1. National Kidney Foundation. K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis 2002; 39(2 Suppl 1): S1 - 266

2. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 1 - 150

3. Tsai WC, Wu HY, Peng YS et al. Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis. Medicine (Baltimore) 2016; 95(11): e3013. doi: 10.1097/MD.0000000000003013

4. Shen Y, Cai R, Sun J et al. Diabetes mellitus as a risk factor for incident chronic kidney disease and end-stage renal disease in women compared with men: a systematic review and meta-analysis. Endocrine 2017; 55(1): 66 - 76. doi: 10.1007/s12020-016-1014-6

5. Chang AR, Grams ME, Ballew SH et al. Adiposity and risk of decline in glomerular filtration rate: meta-analysis of individual participant data in a global consortium. BMJ 2019; 364: k5301. doi: 10.1136/bmj.k5301

6. Nitsch D, Grams M, Sang Y et al. Associations of estimated glomerular filtration rate and albuminuria with mortality and renal failure by sex: a meta-analysis. BMJ 2013; 346: f324. doi: 10.1136/bmj.f324

7. See EJ, Jayasinghe K, Glassford N et al. Long-term risk of adverse outcomes after acute kidney injury: a systematic review and meta-analysis of cohort studies using consensus definitions of exposure. Kidney Int 2019; 95(1): 160 - 172. doi: 10.1016/j.kint.2018.08.036

8. Rashidbeygi E, Safabakhsh M, Delshad Aghdam S et al. Metabolic syndrome and its components are related to a higher risk for albuminuria and proteinuria: Evidence from a meta-analysis on 10,603,067 subjects from 57 studies. Diabetes Metab Syndr 2019; 13(1): 830 - 843. doi: 10.1016/j.dsx.2018.12.006

9. Xia J, Wang L, Ma Z et al. Cigarette smoking and chronic kidney disease in the general population: a systematic review and meta-analysis of prospective cohort studies. Nephrol Dial Transplant 2017; 32(3): 475 - 487. doi: 10.1093/ndt/gfw452

10. Garofalo C, Borrelli S, Pacilio M et al. Hypertension and Prehypertension and Prediction of Development of Decreased Estimated GFR in the General Population: A Meta-analysis of Cohort Studies. Am J Kidney Dis 2016; 67(1): 89 - 97. doi: 10.1053/j.ajkd.2015.08.027

11. Shang W, Li L, Ren Y et al. History of kidney stones and risk of chronic kidney disease: a meta-analysis. PeerJ 2017; 5: e2907. doi: 10.7717/peerj.2907

12. Musso G, Gambino R, Tabibian JH et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med 2014; 11(7): e1001680. doi: 10.1371/journal.pmed.1001680

13. Mantovani A, Zaza G, Byrne CD et al. Nonalcoholic fatty liver disease increases risk of incident chronic kidney disease: A systematic review and meta-analysis. Metabolism 2018; 79: 64 - 76. doi: 10.1016/j.metabol.2017.11.003

14. Yu X, Yuan Z, Lu H et al. Relationship between birth weight and chronic kidney disease: evidence from systematics review and two-sample Mendelian randomization analysis. Hum Mol Genet 2020; 29(13): 2261 - 2274. doi: 10.1093/hmg/ddaa074

15. Major RW, Cheng MRI, Grant RA et al. Cardiovascular disease risk factors in chronic kidney disease: A systematic review and meta-analysis. PLoS One 2018; 13(3): e0192895. doi: 10.1371/journal.pone.0192895

16. Xie X, Atkins E, Lv J et al. Effects of intensive blood pressure lowering on cardiovascular and renal outcomes: updated systematic review and meta-analysis. Lancet 2016; 387(10017): 435 - 43. doi: 10.1016/S0140-6736(15)00805-3

17. Zoungas S, Arima H, Gerstein HC et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol 2017; 5(6): 431 - 437. doi: 10.1016/S2213-8587(17)30104-3

18. Palmer SC, Navaneethan SD, Craig JC et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2014; (5): CD007784. doi: 10.1002/14651858.CD007784.pub2

19. Upadhyay A, Earley A, Lamont JL et al. Lipid-lowering therapy in persons with chronic kidney disease: a systematic review and meta-analysis. Ann Intern Med 2012; 157(4): 251 - 62. doi: 10.7326/0003-4819-157-4-201208210-00005

20. Coca SG, Ismail-Beigi F, Haq N et al. Role of intensive glucose control in development of renal end points in type 2 diabetes mellitus: systematic review and meta-analysis intensive glucose control in type 2 diabetes. Arch Intern Med 2012; 172(10): 761 - 9. doi: 10.1001/archinternmed.2011.2230

21. Alizadeh S, Esmaeili H, Alizadeh M et al. Metabolic phenotypes of obese, overweight, and normal weight individuals and risk of chronic kidney disease: a systematic review and meta-analysis. Arch Endocrinol Metab 2019; 63(4): 427 - 437. doi: 10.20945/2359-3997000000149

22. Navaneethan SD, Yehnert H, Moustarah F et al. Weight loss interventions in chronic kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2009; 4(10): 1565 - 74. doi: 10.2215/CJN.02250409

23. Schwasinger-Schmidt TE, Elhomsy G, Paull-Forney BG. Impact of a Community-Based Weight Loss Program on Renal Function. Cureus 2020; 12(5): e8101. doi: 10.7759/cureus.8101

24. Thomas G, Sehgal AR, Kashyap SR et al. Metabolic syndrome and kidney disease: a systematic review and meta-analysis. Clin J Am Soc Nephrol 2011; 6(10): 2364 - 73. doi: 10.2215/CJN.02180311

25. Staplin N, Haynes R, Herrington WG et al. Smoking and Adverse Outcomes in Patients With CKD: The Study of Heart and Renal Protection (SHARP). Am J Kidney Dis 2016; 68(3): 371 - 80. doi: 10.1053/j.ajkd.2016.02.052

26. Bundy JD, Bazzano LA, Xie D, Cohan J et al. Self-Reported Tobacco, Alcohol, and Illicit Drug Use and Progression of Chronic Kidney Disease. Clin J Am Soc Nephrol 2018; 13(7): 993 - 1001. doi: 10.2215/CJN.11121017

27. United States Renal Date System Report. https://www.usrds.org/annual-data-report/

28. Смирнов А.В., Добронравов В.А., Каюков И.Г. Кардио-ренальный континуум: патогенетические основы превентивной нефрологии. Нефрология 2005; 9(3): 7 - 15

29. Astor BC, Matsushita K, Gansevoort RT et al. Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease population cohorts. Kidney Int 2011; 79(12): 1331 - 40. doi: 10.1038/ki.2010.550

30. Fox CS, Matsushita K, Woodward M et al. Associations of kidney disease measures with mortality and end-stage renal disease in individuals with and without diabetes: a meta-analysis. Lancet 2012; 380(9854): 1662 - 73. doi: 10.1016/S0140-6736(12)61350-6

31. Zhang W, He J, Zhang F et al. Prognostic role of C-reactive protein and interleukin-6 in dialysis patients: a systematic review and meta-analysis. J Nephrol 2013; 26(2): 243 - 53. doi: 10.5301/jn.5000169

32. Li WJ, Chen XM, Nie XY et al. Cardiac troponin and C-reactive protein for predicting all-cause and cardiovascular mortality in patients with chronic kidney disease: a meta-analysis. Clinics (Sao Paulo) 2015; 70(4): 301 - 11. doi: 10.6061/clinics/2015(04)14

33. Jing Z, Wei-jie Y, Nan Z et al. Hemoglobin targets for chronic kidney disease patients with anemia: a systematic review and meta-analysis. PLoS One 2012; 7(8): e43655. doi: 10.1371/journal.pone.0043655

34. Heinz J, Kropf S, Luley C, Dierkes J. Homocysteine-lowering therapy does not lead to reduction in cardiovascular outcomes in chronic kidney disease patients: a meta-analysis of randomised, controlled trials. Br J Nutr 2012; 108(3): 400 - 7. doi: 10.1017/S0007114511007033

35. Coresh J, Heerspink HJL, Sang Y et al. Change in albuminuria and subsequent risk of end-stage kidney disease: an individual participant-level consortium meta-analysis of observational studies. Lancet Diabetes Endocrinol 2019; 7(2): 115 - 127. doi: 10.1016/S2213-8587(18)30313-9

36. Williams B, Mancia G, Spiering W et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39(33): 3021 - 3104. doi: 10.1093/eurheartj/ehy339

37. Ponikowski P, Voors AA, Anker SD et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC) Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur Heart J 2016; 37(27): 2129 - 2200. doi: 10.1093/eurheartj/ehw128

38. Kidney Disease: Improving Global Outcomes (KDIGO) Blood Pressure Work Group. KDIGO Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 337 - 414

39. Hill NR, Fatoba ST, Oke JL et al. Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS One 2016; 11(7): e0158765. doi: 10.1371/journal.pone.0158765

40. Смирнов А.В., Каюков И.Г., Есаян А.М. и др. Превентивный подход в современной нефрологии. Нефрология 2004; 8(3): 7 - 14. doi: 10.24884/1561-6274-2004-8-3-7-14

41. Бикбов Б.Т., Томилина Н.А. Состояние заместительной терапии больных с хронической почечной недостаточностью в Российской Федерации в 1998 - 2007 гг. (Аналитический отчет по данным Российского регистра заместительной почечной терапии). Нефрология и диализ 2009; 11(3): 144 - 233

42. Смирнов А.В., Седов В.М., Лхаахуу Од-Эрдэнэ и др. Снижение скорости клубочковой фильтрации как независимый фактор риска сердечно-сосудистой болезни. Нефрология 2006; 10(4): 7 - 17

43. Смирнов А.В., Добронравов В.А., Каюков И.Г. и др. Эпидемиология и социально-экономические аспекты хронической болезни почек. Нефрология 2006; 10(1): 7 - 13

44. Schieppati A, Remuzzi G. Chronic renal diseases as a public health problem: epidemiology, social, and economic implications. Kidney Int Suppl 2005; (98): S7-S10. doi: 10.1111/j.1523-1755.2005.09801.x

45. Bommer J. Prevalence and socio-economic aspects of chronic kidney disease. Nephrol Dial Transplant 2002; 17 Suppl 11: 8 - 12. doi: 10.1093/ndt/17.suppl_11.8

46. GBD Chronic Kidney Disease Collaboration. Global, regional, and national burden of chronic kidney disease, 1990 - 2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet 2020; 395(10225): 709 - 733. doi: 10.1016/S0140-6736(20)30045-3

47. Yang CW, Harris DCH, Luyckx VA et al. Global case studies for chronic kidney disease/end-stage kidney disease care. Kidney Int Suppl 2020; 10(1): e24 - e48. doi: 10.1016/j.kisu.2019.11.010

48. Андрусев А.М., Перегудова Н.Г., Шинкарев М.Б., Томилина Н.А. Заместительная почечная терапия хронической болезни почек 5 стадии в Российской Федерации 2016 - 2020 гг. Краткий отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества. Нефрология и диализ 2022; 24(4): 555 - 565

49. Смирнов А.В., Добронравов В.А., Бодур-Ооржак А.Ш. и др. Эпидемиология и факторы риска хронических болезней почек: региональный уровень общей проблемы. Тер арх 2005; 6: 20 - 27

50. Нефрология. Национальное руководство. Под ред. Н.А. Мухина. ГЭОТАР-Медиа, 2009, 720 с

51. National Center for Health Statistics. WHO Collaborating Centre for the WHO Family of International Classifications. https://www.who.int/classifications/icd/ICD-10%20Updates%202007.pdf

52. Inker LA, Heerspink HJL, Tighiouart H et al. GFR Slope as a Surrogate End Point for Kidney Disease Progression in Clinical Trials: A Meta-Analysis of Treatment Effects of Randomized Controlled Trials. J Am Soc Nephrol 2019; 30(9): 1735 - 1745. doi: 10.1681/ASN.2019010007

53. Heerspink HJL, Greene T, Tighiouart H et al. Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials. Lancet Diabetes Endocrinol 2019; 7(2): 128 - 139. doi: 10.1016/S2213-8587(18)30314-0

54. Yarnoff BO, Hoerger TJ, Simpson SK et al. The cost-effectiveness of using chronic kidney disease risk scores to screen for early-stage chronic kidney disease. BMC Nephrol 2017; 18(1): 85. doi: 10.1186/s12882-017-0497-6

55. Galbraith LE, Ronksley PE, Barnieh LJ et al. The See Kidney Disease Targeted Screening Program for CKD. Clin J Am Soc Nephrol 2016; 11(6): 964 - 72. doi: 10.2215/CJN.11961115

56. Manns B, Hemmelgarn B, Tonelli M et al. Population based screening for chronic kidney disease: cost effectiveness study. BMJ 2010; 341: c5869. doi: 10.1136/bmj.c5869

57. Boulware LE, Jaar BG, Tarver-Carr ME et al. Screening for proteinuria in US adults: a cost-effectiveness analysis. JAMA 2003; 290(23): 3101 - 14. doi: 10.1001/jama.290.23.3101

58. Wu HY, Huang JW, Peng YS et al. Microalbuminuria screening for detecting chronic kidney disease in the general population: a systematic review. Ren Fail 2013; 35(5): 607 - 14. doi: 10.3109/0886022X.2013.779907

59. Komenda P, Ferguson TW, Macdonald K et al. Cost-effectiveness of primary screening for CKD: a systematic review. Am J Kidney Dis 2014; 63(5): 789 - 97. doi: 10.1053/j.ajkd.2013.12.012

60. Gheewala PA, Zaidi STR, Jose MD et al. Effectiveness of targeted screening for chronic kidney disease in the community setting: a systematic review. J Nephrol 2018; 31(1): 27 - 36. doi: 10.1007/s40620-017-0375-0

61. Yang P, Zou H, Xiao B, Xu G. Comparative Efficacy and Safety of Therapies in IgA Nephropathy: A Network Meta-analysis of Randomized Controlled Trials. Kidney Int Rep 2018; 3(4): 794 - 803. doi: 10.1016/j.ekir.2018.03.006

62. Sridharan K, Sivaramakrishnan G. Drug Therapies for Patients with IgA Nephropathy: A Network Meta-analysis of Randomized Clinical Trials. Curr Clin Pharmacol 2020; 15(2): 132 - 144. doi: 10.2174/1574884715666191223103914

63. Zhang Z, Yang Y, Jiang SM, Li WG. Efficacy and safety of immunosuppressive treatment in IgA nephropathy: a meta-analysis of randomized controlled trials. BMC Nephrol 2019; 20(1): 333. doi: 10.1186/s12882-019-1519-3

64. Zheng Q, Yang H, Liu W et al. Comparative efficacy of 13 immunosuppressive agents for idiopathic membranous nephropathy in adults with nephrotic syndrome: a systematic review and network meta-analysis. BMJ Open 2019; 9(9): e030919. doi: 10.1136/bmjopen-2019-030919

65. Chen Y, Schieppati A, Cai G et al. Immunosuppression for membranous nephropathy: a systematic review and meta-analysis of 36 clinical trials. Clin J Am Soc Nephrol 2013; 8(5): 787 - 96. doi: 10.2215/CJN.07570712

66. Laurin LP, Nachman PH, Foster BJ. Calcineurin Inhibitors in the Treatment of Primary Focal Segmental Glomerulosclerosis: A Systematic Review and Meta-analysis of the Literature. Can J Kidney Health Dis 2017; 4: 2054358117692559. doi: 10.1177/2054358117692559

67. Palmer SC, Tunnicliffe DJ, Singh-Grewal D et al. Induction and Maintenance Immunosuppression Treatment of Proliferative Lupus Nephritis: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis 2017; 70(3): 324 - 336. doi: 10.1053/j.ajkd.2016.12.008

68. Li Y, Xu S, Xu G. Comparison of Different Uses of Cyclophosphamide in Lupus Nephritis: A Meta-Analysis of Randomized Controlled Trials. Endocr Metab Immune Disord Drug Targets 2020; 20(5): 687 - 702. doi: 10.2174/1871530319666191107110420

69. Hazlewood GS, Metzler C, Tomlinson GA et al. Non-biologic remission maintenance therapy in adult patients with ANCA-associated vasculitis: a systematic review and network meta-analysis. Joint Bone Spine 2014; 81(4): 337 - 41. doi: 10.1016/j.jbspin.2013.11.006

70. Fabrizi F, Ganeshan SV, Lunghi G et al. Antiviral therapy of hepatitis C in chronic kidney diseases: meta-analysis of controlled clinical trials. J Viral Hepat 2008; 15(8): 600 - 6. doi: 10.1111/j.1365-2893.2008.00990.x

71. Zhang T, Yang X, Zhang M, Zhou W, Jin Y, Zhou H, Zhou Y, Wang Q, Mou S. Effects of receiving renal biopsy on the prognosis of chronic kidney disease patients with impaired renal function. BMC Nephrol. 2023 Mar 15; 24(1): 56. doi: 10.1186/s12882-023-03097-2

72. Lv J, Ehteshami P, Sarnak MJ et al. Effects of intensive blood pressure lowering on the progression of chronic kidney disease: a systematic review and meta-analysis. CMAJ 2013; 185(11): 949 - 57. doi: 10.1503/cmaj.121468

73. Нефрология. Клинические рекомендации. Под ред. Шилов Е.М., Смирнов А.В., Козловская Н.Л. ГЭОТАР-Медиа, 202

74. Malhotra R, Nguyen HA, Benavente O et al. Association Between More Intensive vs Less Intensive Blood Pressure Lowering and Risk of Mortality in Chronic Kidney Disease Stages 3 to 5: A Systematic Review and Meta-analysis. JAMA Intern Med 2017; 177(10): 1498 - 1505. doi: 10.1001/jamainternmed.2017.4377

75. Zhang X, Xiang C, Zhou YH et al. Effect of statins on cardiovascular events in patients with mild to moderate chronic kidney disease: a systematic review and meta-analysis of randomized clinical trials. BMC Cardiovasc Disord 2014; 14: 19. doi: 10.1186/1471-2261-14-19

76. Major RW, Cheung CK, Gray LJ, Brunskill NJ. Statins and Cardiovascular Primary Prevention in CKD: A Meta-Analysis. Clin J Am Soc Nephrol 2015; 10(5): 732 - 9. doi: 10.2215/CJN.07460714

77. Ladhani M, Craig JC, Irving M et al. Obesity and the risk of cardiovascular and all-cause mortality in chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 2017; 32(3): 439 - 449. doi: 10.1093/ndt/gfw075

78. Kovesdy CP, Matsushita K, Sang Y et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J 2018; 39(17): 1535 - 1542. doi: 10.1093/eurheartj/ehy100

79. Hu MK, Witham MD, Soiza RL. Oral Bicarbonate Therapy in Non-Haemodialysis Dependent Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. J Clin Med 2019; 8(2): 208. doi: 10.3390/jcm8020208

80. Duranton F, Rodriguez-Ortiz ME, Duny Y et al. Vitamin D treatment and mortality in chronic kidney disease: a systematic review and meta-analysis. Am J Nephrol 2013; 37(3): 239 - 48. doi: 10.1159/000346846

81. Li XH, Feng L, Yang ZH, Liao YH. Effect of active vitamin D on cardiovascular outcomes in predialysis chronic kidney diseases: A systematic review and meta-analysis. Nephrology (Carlton) 2015; 20(10): 706 - 714. doi: 10.1111/nep.12505

82. Xu L, Wan X, Huang Z et al. Impact of vitamin D on chronic kidney diseases in non-dialysis patients: a meta-analysis of randomized controlled trials. PLoS One 2013; 8(4): e61387. doi: 10.1371/journal.pone.0061387

83. Liu X, Zhai T, Ma R et al. Effects of uric acid-lowering therapy on the progression of chronic kidney disease: a systematic review and meta-analysis. Ren Fail 2018; 40(1): 289 - 297. doi: 10.1080/0886022X.2018.1456463

84. Zhang YF, He F, Ding HH et al. Effect of uric-acid-lowering therapy on progression of chronic kidney disease: a meta-analysis. J Huazhong Univ Sci Technolog Med Sci 2014; 34(4): 476 - 481. doi: 10.1007/s11596-014-1302-4

85. Lu R, Zhang Y, Zhu X et al. Effects of mineralocorticoid receptor antagonists on left ventricular mass in chronic kidney disease patients: a systematic review and meta-analysis. Int Urol Nephrol 2016; 48(9): 1499 - 509. doi: 10.1007/s11255-016-1319-7

86. Wang XR, Zhang JJ, Xu XX, Wu YG. Prevalence of coronary artery calcification and its association with mortality, cardiovascular events in patients with chronic kidney disease: a systematic review and meta-analysis. Ren Fail 2019; 41(1): 244 - 256. doi: 10.1080/0886022X.2019.1595646

87. Bansal N, Katz R, Robinson-Cohen C et al. Absolute Rates of Heart Failure, Coronary Heart Disease, and Stroke in Chronic Kidney Disease: An Analysis of 3 Community-Based Cohort Studies. JAMA Cardiol 2017; 2(3): 314 - 318. doi: 10.1001/jamacardio.2016.4652

88. Charytan DM, Wallentin L, Lagerqvist B et al. Early angiography in patients with chronic kidney disease: a collaborative systematic review. Clin J Am Soc Nephrol 2009; 4(6): 1032 - 43. doi: 10.2215/CJN.05551008

89. Collier G, Greenan MC, Brady JJ et al. A study of the relationship between albuminuria, proteinuria and urinary reagent strips. Ann Clin Biochem 2009; 46(Pt 3): 247 - 9. doi: 10.1258/acb.2009.008189

90. McTaggart MP, Newall RG, Hirst JA et al. Diagnostic accuracy of point-of-care tests for detecting albuminuria: a systematic review and meta-analysis. Ann Intern Med 2014; 160(8): 550 - 7. doi: 10.7326/M13-2331

91. Kim Y, Park S, Kim MH et al. Can a semi-quantitative method replace the current quantitative method for the annual screening of microalbuminuria in patients with diabetes? Diagnostic accuracy and cost-saving analysis considering the potential health burden. PLoS One 2020; 15(1): e0227694. doi: 10.1371/journal.pone.0227694

92. White SL, Yu R, Craig JC et al. Diagnostic accuracy of urine dipsticks for detection of albuminuria in the general community. Am J Kidney Dis 2011; 58(1): 19 - 28. doi: 10.1053/j.ajkd.2010.12.026

93. Park JI, Baek H, Kim BR, Jung HH. Comparison of urine dipstick and albumin: creatinine ratio for chronic kidney disease screening: A population-based study. PLoS One 2017; 12(2): e0171106. doi: 10.1371/journal.pone.0171106

94. Koeda Y, Tanaka F, Segawa T et al. Comparison between urine albumin-to-creatinine ratio and urine protein dipstick testing for prevalence and ability to predict the risk for chronic kidney disease in the general population (Iwate-KENCO study): a prospective community-based cohort study. BMC Nephrol 2016; 17(1): 46. doi: 10.1186/s12882-016-0261-3

95. Usui T, Yoshida Y, Nishi H et al. Diagnostic accuracy of urine dipstick for proteinuria category in Japanese workers. Clin Exp Nephrol 2020; 24(2): 151 - 156. doi: 10.1007/s10157-019-01809-3

96. Naruse M, Mukoyama M, Morinaga J et al. Usefulness of the quantitative measurement of urine protein at a community-based health checkup: a cross-sectional study. Clin Exp Nephrol 2020; 24(1): 45 - 52. doi: 10.1007/s10157-019-01789-4

97. Wu HY, Peng YS, Chiang CK et al. Diagnostic performance of random urine samples using albumin concentration vs ratio of albumin to creatinine for microalbuminuria screening in patients with diabetes mellitus: a systematic review and meta-analysis. JAMA Intern Med 2014; 174(7): 1108 - 15. doi: 10.1001/jamainternmed.2014.1363

98. Wu MT, Lam KK, Lee WC et al. Albuminuria, proteinuria, and urinary albumin to protein ratio in chronic kidney disease. J Clin Lab Anal 2012; 26(2): 82 - 92. doi: 10.1002/jcla.21487

99. Kim SM, Lee CH, Lee JP et al. The association between albumin to creatinine ratio and total protein to creatinine ratio in patients with chronic kidney disease. Clin Nephrol 2012; 78(5): 346 - 52. doi: 10.5414/CN107507

100. Atkins RC, Briganti EM, Zimmet PZ, Chadban SJ. Association between albuminuria and proteinuria in the general population: the AusDiab Study. Nephrol Dial Transplant 2003; 18(10): 2170 - 4. doi: 10.1093/ndt/gfg314

101. Fisher H, Hsu CY, Vittinghoff E et al. Comparison of associations of urine protein-creatinine ratio versus albumin-creatinine ratio with complications of CKD: a cross-sectional analysis. Am J Kidney Dis 2013; 62(6): 1102 - 8. doi: 10.1053/j.ajkd.2013.07.013

102. Methven S, MacGregor MS, Traynor JP et al. Comparison of urinary albumin and urinary total protein as predictors of patient outcomes in CKD. Am J Kidney Dis 2011; 57(1): 21 - 8. doi: 10.1053/j.ajkd.2010.08.009

103. Weaver RG, James MT, Ravani P et al. Estimating Urine Albumin-to-Creatinine Ratio from Protein-to-Creatinine Ratio: Development of Equations using Same-Day Measurements. J Am Soc Nephrol 2020; 31(3): 591 - 601. doi: 10.1681/ASN.2019060605

104. McFadden EC, Hirst JA, Verbakel JY et al. Systematic Review and Metaanalysis Comparing the Bias and Accuracy of the Modification of Diet in Renal Disease and Chronic Kidney Disease Epidemiology Collaboration Equations in Community-Based Populations. Clin Chem 2018; 64(3): 475 - 485. doi: 10.1373/clinchem.2017.276683

105. Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann Intern Med 2009; 150(9): 604 - 12. doi: 10.7326/0003-4819-150-9-200905050-00006

106. Stevens LA, Schmid CH, Greene T et al. Comparative performance of the CKD Epidemiology Collaboration (CKD-EPI) and the Modification of Diet in Renal Disease (MDRD) Study equations for estimating GFR levels above 60 mL/min/1.73 m2. Am J Kidney Dis 2010; 56(3): 486 - 95. doi: 10.1053/j.ajkd.2010.03.026

107. Matsushita K, Mahmoodi BK, Woodward M et al. Comparison of risk prediction using the CKD-EPI equation and the MDRD study equation for estimated glomerular filtration rate. JAMA 2012; 307(18): 1941 - 51. doi: 10.1001/jama.2012.3954

108. Levey AS, Stevens LA. Estimating GFR using the CKD Epidemiology Collaboration (CKD-EPI) creatinine equation: more accurate GFR estimates, lower CKD prevalence estimates, and better risk predictions. Am J Kidney Dis 2010; 55(4): 622 - 7. doi: 10.1053/j.ajkd.2010.02.337

109. Zhang M, Cao X, Cai G et al. Clinical evaluation of serum cystatin C and creatinine in patients with chronic kidney disease: a meta-analysis. J Int Med Res 2013; 41(4): 944 - 55. doi: 10.1177/0300060513480922

110. Qiu X, Liu C, Ye Y et al. The diagnostic value of serum creatinine and cystatin c in evaluating glomerular filtration rate in patients with chronic kidney disease: a systematic literature review and meta-analysis. Oncotarget 2017; 8(42): 72985 - 72999. doi: 10.18632/oncotarget.20271

111. Wei L, Ye X, Pei X et al. Diagnostic accuracy of serum cystatin C in chronic kidney disease: a meta-analysis. Clin Nephrol 2015; 84(2): 86 - 94. doi: 10.5414/cn108525

112. Dharnidharka VR, Kwon C, Stevens G. Serum cystatin C is superior to serum creatinine as a marker of kidney function: a meta-analysis. Am J Kidney Dis 2002; 40(2): 221 - 6. doi: 10.1053/ajkd.2002.34487

113. Inker LA, Schmid CH, Tighiouart H et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med 2012; 367(1): 20 - 9. doi: 10.1056/NEJMoa1114248

114. Miller WG, Myers GL, Ashwood ER et al. Creatinine measurement: state of the art in accuracy and interlaboratory harmonization. Arch Pathol Lab Med 2005; 129(3): 297 - 304. doi: 10.1043/1543-2165(2005)129<297:CMSOTA>2.0.CO;2

115. L, Delanaye P, Boutten A et al. A multicentric evaluation of IDMS-traceable creatinine enzymatic assays. Clin Chim Acta 2011; 412(23-24): 2070 - 5. doi: 10.1016/j.cca.2011.07.012

116. Lee ES, Collier CP, White CA. Creatinine Assay Attainment of Analytical Performance Goals Following Implementation of IDMS Standardization: Further Improvements Required. Can J Kidney Health Dis 2017; 4: 2054358117693353. doi: 10.1177/2054358117693353

117. Stevens LA, Manzi J, Levey AS et al. Impact of creatinine calibration on performance of GFR estimating equations in a pooled individual patient database. Am J Kidney Dis 2007; 50(1): 21 - 35. doi: 10.1053/j.ajkd.2007.04.004

118. Ou M, Song Y, Li S et al. LC-MS/MS Method for Serum Creatinine: Comparison with Enzymatic Method and Jaffe Method. PLoS One 2015; 10(7): e0133912. doi: 10.1371/journal.pone.0133912

119. Jones GRD. Creatinine assays - global progress on implementing IDMS traceability. Clin Chem Lab Med 2015; 53(Special)Suppl: S1 - 1450

120. Welch MJ, Cohen A, Hertz HS et al. Determination of serum creatinine by isotope dilution mass spectrometry as a candidate definitive method. Anal Chem 1986; 58(8): 1681 - 5. doi: 10.1021/ac00121a018

121. Lawson N, Lang T, Broughton A et al. Creatinine assays: time for action? Ann Clin Biochem 2002; 39(Pt 6): 599 - 602. doi: 10.1177/000456320203900609

122. Lamb EJ, Wood J, Stowe HJ et al. Susceptibility of glomerular filtration rate estimations to variations in creatinine methodology: a study in older patients. Ann Clin Biochem 2005; 42(Pt 1): 11 - 8. doi: 10.1258/0004563053026899

123. Kuster N, Cristol JP, Cavalier E et al. Enzymatic creatinine assays allow estimation of glomerular filtration rate in stages 1 and 2 chronic kidney disease using CKD-EPI equation. Clin Chim Acta 2014; 428: 89 - 95. doi: 10.1016/j.cca.2013.11.002

124. Soveri I, Berg UB, J et al. Measuring GFR: a systematic review. Am J Kidney Dis 2014; 64(3): 411 - 24. doi: 10.1053/j.ajkd.2014.04.010

125. Palmer SC, Gardner S, Tonelli M et al. Phosphate-Binding Agents in Adults With CKD: A Network Meta-analysis of Randomized Trials. Am J Kidney Dis 2016; 68(5): 691 - 702. doi: 10.1053/j.ajkd.2016.05.015

126. Matsushita K, Coresh J, Sang Y et al. Estimated glomerular filtration rate and albuminuria for prediction of cardiovascular outcomes: a collaborative meta-analysis of individual participant data. Lancet Diabetes Endocrinol 2015; 3(7): 514 - 25. doi: 10.1016/S2213-8587(15)00040-6

127. F, Chimeno MM, D et al. Cholesterol-Lowering Treatment in Chronic Kidney Disease: Multistage Pairwise and Network Meta-Analyses. Sci Rep 2019 Jun 20; 9(1): 8951. doi: 10.1038/s41598-019-45431-5

128. Fishbane S, Spinowitz B. Update on Anemia in ESRD and Earlier Stages of CKD: Core Curriculum 2018. Am J Kidney Dis 2018; 71(3): 423 - 435. doi: 10.1053/j.ajkd.2017.09.026

129. Locatelli F, P, Covic A et al. Kidney Disease: Improving Global Outcomes guidelines on anaemia management in chronic kidney disease: a European Renal Best Practice position statement. Nephrol Dial Transplant 2013; 28(6): 1346 - 59. doi: 10.1093/ndt/gft033

130. J, J. Differential diagnosis of anemia. Vnitr Lek 2018; 64(5): 468 - 475

131. Archer NM, Brugnara C. Diagnosis of iron-deficient states. Crit Rev Clin Lab Sci 2015; 52(5): 256 - 72. doi: 10.3109/10408363.2015.1038744

132. McCullough K, Bolisetty S. Ferritins in Kidney Disease. Semin Nephrol 2020; 40(2): 160 - 172. doi: 10.1016/j.semnephrol.2020.01.007

133. Natoli JL, Boer R, Nathanson BH et al. Is there an association between elevated or low serum levels of phosphorus, parathyroid hormone, and calcium and mortality in patients with end stage renal disease? A meta-analysis. BMC Nephrol 2013; 14: 88. doi: 10.1186/1471-2369-14-88

134. Pilz S, Iodice S, Zittermann A et al. Vitamin D status and mortality risk in CKD: a meta-analysis of prospective studies. Am J Kidney Dis 2011; 58(3): 374 - 82. doi: 10.1053/j.ajkd.2011.03.020

135. Zhang Y, Darssan D, Pascoe EM et al. Vitamin D status and mortality risk among patients on dialysis: a systematic review and meta-analysis of observational studies. Nephrol Dial Transplant 2018; 33(10): 1742 - 1751. doi: 10.1093/ndt/gfy016

136. Fan Y, Jin X, Jiang M, Fang N. Elevated serum alkaline phosphatase and cardiovascular or all-cause mortality risk in dialysis patients: A meta-analysis. Sci Rep 2017; 7(1): 13224. doi: 10.1038/s41598-017-13387-z

137. McMahon EJ, Campbell KL, Bauer JD, Mudge DW. Altered dietary salt intake for people with chronic kidney disease. Cochrane Database Syst Rev 2015; (2): CD010070. doi: 10.1002/14651858.CD010070.pub2

138. Garofalo C, Borrelli S, Provenzano M et al. Dietary Salt Restriction in Chronic Kidney Disease: A Meta-Analysis of Randomized Clinical Trials. Nutrients 2018; 10(6): 732. doi: 10.3390/nu10060732

139. Navaneethan SD, Shao J, Buysse J, Bushinsky DA. Effects of Treatment of Metabolic Acidosis in CKD: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2019; 14(7): 1011 - 1020. doi: 10.2215/CJN.13091118

140. Susantitaphong P, Sewaralthahab K, Balk EM et al. Short- and long-term effects of alkali therapy in chronic kidney disease: a systematic review. Am J Nephrol 2012; 35(6): 540 - 7. doi: 10.1159/000339329

141. Su X, Xu B, Yan B et al. Effects of uric acid-lowering therapy in patients with chronic kidney disease: A meta-analysis. PLoS One 2017; 12(11): e0187550. doi: 10.1371/journal.pone.0187550

142. Kidney Disease: Improving Global Outcomes (KDIGO) Anemia Work Group. KDIGO Clinical Practice Guideline for Anemia in Chronic Kidney Disease. Kidney Int Suppl 2012; 2: 279 - 335

143. Kidney Disease: Improving Global Outcomes (KDIGO) Lipid Work Group. KDIGO Clinical Practice Guideline for Lipid Management in Chronic Kidney Disease. Kidney Int Suppl 2013; 3: 259 - 305

144. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Update Work Group. KDIGO 2017 Clinical Practice Guideline Update for the Diagnosis, Evaluation, Prevention, and Treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2017; 7(3): e1. doi: 10.1016/j.kisu.2017.10.001

145. Moghazi S, Jones E, Schroepple J et al. Correlation of renal histopathology with sonographic findings. Kidney Int 2005; 67(4): 1515 - 1520. doi: 10.1111/j.1523-1755.2005.00230.x

146. Page JE, Morgan SH, Eastwood JB et al. Ultrasound findings in renal parenchymal disease: comparison with histological appearances. Clin Radiol 1994; 49(12): 867 - 70. doi: 10.1016/s0009-9260(05)82877-6

147. Vasbinder GB, Nelemans PJ, Kessels AG et al. Diagnostic tests for renal artery stenosis in patients suspected of having renovascular hypertension: a meta-analysis. Ann Intern Med 2001 Sep; 135(6): 401 - 11. doi: 10.7326/0003-4819-135-6-200109180-00009

148. Williams GJ, Macaskill P, Chan SF et al. Comparative accuracy of renal duplex sonographic parameters in the diagnosis of renal artery stenosis: paired and unpaired analysis. AJR Am J Roentgenol 2007; 188(3): 798 - 811. doi: 10.2214/AJR.06.0355

149. Tan KT, van Beek EJ, Brown PW et al. Magnetic resonance angiography for the diagnosis of renal artery stenosis: a meta-analysis. Clin Radiol 2002; 57(7): 617 - 24. doi: 10.1053/crad.2002.0941

150. James MT, Grams ME, Woodward M et al. A Meta-analysis of the Association of Estimated GFR, Albuminuria, Diabetes Mellitus, and Hypertension With Acute Kidney Injury. Am J Kidney Dis 2015 Oct; 66(4): 602 - 12. doi: 10.1053/j.ajkd.2015.02.338

151. McCullough PA, Bertrand ME, Brinker JA, Stacul F. A meta-analysis of the renal safety of isosmolar iodixanol compared with low-osmolar contrast media. J Am Coll Cardiol 2006; 48(4): 692 - 9. doi: 10.1016/j.jacc.2006.02.073

152. Han XF, Zhang XX, Liu KM et al. Contrast-induced nephropathy in patients with diabetes mellitus between iso- and low-osmolar contrast media: A meta-analysis of full-text prospective, randomized controlled trials. PLoS One 2018; 13(3): e0194330. doi: 10.1371/journal.pone.0194330

153. From AM, Al Badarin FJ, McDonald FS et al. Iodixanol versus low-osmolar contrast media for prevention of contrast induced nephropathy: meta-analysis of randomized, controlled trials. Circ Cardiovasc Interv 2010; 3(4): 351 - 8. doi: 10.1161/CIRCINTERVENTIONS.109.917070

154. Zhang J, Jiang Y, Rui Q et al. Iodixanol versus iopromide in patients with renal insufficiency undergoing coronary angiography with or without PCI. Medicine (Baltimore) 2018; 97(18): e0617. doi: 10.1097/MD.0000000000010617

155. Khan SU, Khan MU, Rahman H et al. A Bayesian network meta-analysis of preventive strategies for contrast-induced nephropathy after cardiac catheterization. Cardiovasc Revasc Med 2019; 20(1): 29 - 37. doi: 10.1016/j.carrev.2018.06.005

156. Giacoppo D, Gargiulo G, Buccheri S et al. Preventive Strategies for Contrast-Induced Acute Kidney Injury in Patients Undergoing Percutaneous Coronary Procedures: Evidence From a Hierarchical Bayesian Network Meta-Analysis of 124 Trials and 28 240 Patients. Circ Cardiovasc Interv 2017; 10(5): e004383. doi: 10.1161/CIRCINTERVENTIONS.116.004383

157. Su X, Xie X, Liu L et al. Comparative Effectiveness of 12 Treatment Strategies for Preventing Contrast-Induced Acute Kidney Injury: A Systematic Review and Bayesian Network Meta-analysis. Am J Kidney Dis 2017; 69(1): 69 - 77. doi: 10.1053/j.ajkd.2016.07.033

158. Ma WQ, Zhao Y, Wang Y et al. Comparative efficacy of pharmacological interventions for contrast-induced nephropathy prevention after coronary angiography: a network meta-analysis from randomized trials. Int Urol Nephrol 2018; 50(6): 1085 - 1095. doi: 10.1007/s11255-018-1814-0

159. Zhou X, Dai J, Xu Х et al. Comparative Efficacy of Statins for Prevention of Contrast-Induced Acute Kidney Injury in Patients With Chronic Kidney Disease: A Network Meta-Analysis. Angiology 2019; 70(4): 305 - 316. doi: 10.1177/0003319718801246

160. Navarese EP, Gurbel PA, Andreotti F et al. Prevention of contrast-induced acute kidney injury in patients undergoing cardiovascular procedures-a systematic review and network meta-analysis. PLoS One 2017; 12(2): e0168726. doi: 10.1371/journal.pone.0168726

161. Jiang Y, Chen M, Zhang Y et al. Meta-analysis of prophylactic hydration versus no hydration on contrast-induced acute kidney injury. Coron Artery Dis 2017; 28(8): 649 - 657. doi: 10.1097/MCA.0000000000000514

162. Woolen SA, Shankar PR, Gagnier JJ et al. Risk of Nephrogenic Systemic Fibrosis in Patients With Stage 4 or 5 Chronic Kidney Disease Receiving a Group II Gadolinium-Based Contrast Agent: A Systematic Review and Meta-analysis. JAMA Intern Med 2020; 180(2): 223 - 230. doi: 10.1001/jamainternmed.2019.5284

163. Agarwal R, Brunelli SM, Williams K et al. Gadolinium-based contrast agents and nephrogenic systemic fibrosis: a systematic review and meta-analysis. Nephrol Dial Transplant 2009; 24(3): 856 - 63. doi: 10.1093/ndt/gfn593

164. Soulez G, Bloomgarden DC, Rofsky NM et al. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3 - 5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol. AJR Am J Roentgenol 2015; 205(3): 469 - 78. doi: 10.2214/AJR.14.14268

165. Attari H, Cao Y, Elmholdt TR et al. A Systematic Review of 639 Patients with Biopsy-confirmed Nephrogenic Systemic Fibrosis. Radiology 2019; 292(2): 376 - 386. doi: 10.1148/radiol.2019182916

166. Bangash F, Agarwal R. Masked hypertension and white-coat hypertension in chronic kidney disease: a meta-analysis. Clin J Am Soc Nephrol 2009; 4(3): 656 - 64. doi: 10.2215/CJN.05391008

167. A, Ayala DE, L et al. Comparison of ambulatory blood pressure parameters of hypertensive patients with and without chronic kidney disease. Chronobiol Int 2013; 30(1-2): 145 - 58. doi: 10.3109/07420528.2012.703083

168. Gorostidi M, Sarafidis PA, de la Sierra A et al. Differences between office and 24-hour blood pressure control in hypertensive patients with CKD: A 5,693-patient cross-sectional analysis from Spain. Am J Kidney Dis 2013; 62(2): 285 - 94. doi: 10.1053/j.ajkd.2013.03.025

169. Son HE, Ryu JY, Go S et al. Association of ambulatory blood pressure monitoring with renal outcome in patients with chronic kidney disease. Kidney Res Clin Pract 2020; 39(1): 70 - 80. doi: 10.23876/j.krcp.19.103

170. Gabbai FB, Rahman M, Hu B et al. Relationship between ambulatory BP and clinical outcomes in patients with hypertensive CKD. Clin J Am Soc Nephrol 2012; 7(11): 1770 - 6. doi: 10.2215/CJN.11301111

171. Minutolo R, Gabbai FB, Chiodini P et al. Reassessment of Ambulatory Blood Pressure Improves Renal Risk Stratification in Nondialysis Chronic Kidney Disease: Long-Term Cohort Study. Hypertension 2015; 66(3): 557 - 62. doi: 10.1161/HYPERTENSIONAHA.115.05820

172. Артериальная гипертензия у взрослых. Клинические рекомендации. https://scardio.ru/content/Guidelines/Clinic_rek_AG_2020.pdf

173. Grunwald JE, Pistilli M, Ying GS et al. Retinopathy and the risk of cardiovascular disease in patients with chronic kidney disease (from the Chronic Renal Insufficiency Cohort study). Am J Cardiol 2015; 116(10): 1527 - 33. doi: 10.1016/j.amjcard.2015.08.015

174. Kim Y, Cho JS, Cho WK et al. Retinopathy and left ventricular hypertrophy in patients with chronic kidney disease: Interrelationship and impact on clinical outcomes. Int J Cardiol 2017; 249: 372 - 376. doi: 10.1016/j.ijcard.2017.06.123

175. Hwang HS, Kim SY, Hong YA et al. Clinical impact of coexisting retinopathy and vascular calcification on chronic kidney disease progression and cardiovascular events. Nutr Metab Cardiovasc Dis 2016; 26(7): 590 - 596. doi: 10.1016/j.numecd.2016.02.005

176. Zhang A, Wang S, Li H et al. Aortic arch calcification and risk of cardiovascular or all-cause and mortality in dialysis patients: A meta-analysis. Sci Rep 2016; 6: 35375. doi: 10.1038/srep35375

177. Niu Q, Hong Y, Lee CH et al. Abdominal aortic calcification can predict all-cause mortality and CV events in dialysis patients: A systematic review and meta-analysis. PLoS One 2018; 13(9): e0204526. doi: 10.1371/journal.pone.0204526

178. Rennenberg RJ, Kessels AG, Schurgers LJ et al. Vascular calcifications as a marker of increased cardiovascular risk: a meta-analysis. Vasc Health Risk Manag 2009; 5(1): 185 - 97. doi: 10.2147/vhrm.s4822

179. Wang Z, Jiang A, Wei F, Chen H. Cardiac valve calcification and risk of cardiovascular or all-cause mortality in dialysis patients: a meta-analysis. BMC Cardiovasc Disord 2018; 18(1): 12. doi: 10.1186/s12872-018-0747-y

180. Samad Z, Sivak JA, Phelan M et al. Prevalence and Outcomes of Left-Sided Valvular Heart Disease Associated With Chronic Kidney Disease. J Am Heart Assoc 2017; 6(10): e006044. doi: 10.1161/JAHA.117.006044

181. Marwick TH, Amann K, Bangalore S et al. Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2019; 96(4): 836 - 849. doi: 10.1016/j.kint.2019.06.025

182. Payne J, Sharma S, De Leon D et al. Association of echocardiographic abnormalities with mortality in men with non-dialysis-dependent chronic kidney disease. Nephrol Dial Transplant 2012; 27(2): 694 - 700. doi: 10.1093/ndt/gfr282

183. Hensen LCR, Goossens K, Delgado V et al. Prevalence of left ventricular systolic dysfunction in pre-dialysis and dialysis patients with preserved left ventricular ejection fraction. Eur J Heart Fail 2018; 20(3): 560 - 568. doi: 10.1002/ejhf.1077

184. Unger ED, Dubin RF, Deo R et al. Association of chronic kidney disease with abnormal cardiac mechanics and adverse outcomes in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 2016; 18(1): 103 - 12. doi: 10.1002/ejhf.445

185. Panoulas VF, Sulemane S, Konstantinou K et al. Early detection of subclinical left ventricular myocardial dysfunction in patients with chronic kidney disease. Eur Heart J Cardiovasc Imaging 2015; 16(5): 539 - 48. doi: 10.1093/ehjci/jeu229

186. Krishnasamy R, Isbel NM, Hawley CM et al. Left Ventricular Global Longitudinal Strain (GLS) Is a Superior Predictor of All-Cause and Cardiovascular Mortality When Compared to Ejection Fraction in Advanced Chronic Kidney Disease. PLoS One 2015; 10(5): e0127044. doi: 10.1371/journal.pone.0127044

187. Masson P, Webster AC, Hong M et al. Chronic kidney disease and the risk of stroke: a systematic review and meta-analysis. Nephrol Dial Transplant 2015; 30(7): 1162 - 9. doi: 10.1093/ndt/gfv009

188. Bucur RC, Panjwani DD, Turner L et al. Low bone mineral density and fractures in stages 3 - 5 CKD: an updated systematic review and meta-analysis. Osteoporos Int 2015; 26(2): 449 - 58. doi: 10.1007/s00198-014-2813-3

189. Jamal SA, Hayden JA, Beyene J. Low bone mineral density and fractures in long-term hemodialysis patients: a meta-analysis. Am J Kidney Dis 2007; 49(5): 674 - 81. doi: 10.1053/j.ajkd.2007.02.264

190. Li X, Li J, Li Y et al. The role of preoperative ultrasound, contrast-enhanced ultrasound, and 99mTc-MIBI scanning with single-photon emission computed tomography/X-ray computed tomography localization in refractory secondary hyperparathyroidism. Clinical hemorheology and microcirculation 2020; 75(1): 35 - 46. doi: 10.3233/CH-190723

191. Lee JB, Kim WY, Lee YM. The role of preoperative ultrasonography, computed tomography, and sestamibi scintigraphy localization in secondary hyperparathyroidism. Annals of surgical treatment and research 2015; 89(6): 300

192. Alkhalili E, Tasci Y, Aksoy E et al. The utility of neck ultrasound and sestamibi scans in patients with secondary and tertiary hyperparathyroidism. World journal of surgery 2015; 39(3): 701 - 705. doi: 10.1007/s00268-014-2878-3

193. Luciano RL, Moeckel GW. Update on the Native Kidney Biopsy: Core Curriculum 2019. Am J Kidney Dis 2019; 73(3): 404 - 415. doi: 10.1053/j.ajkd.2018.10.011

194. Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int Suppl 2012; 2: 139 - 1274

195. Xie X, Liu Y, Perkovic V et al. Renin-Angiotensin System Inhibitors and Kidney and Cardiovascular Outcomes in Patients With CKD: A Bayesian Network Meta-analysis of Randomized Clinical Trials. Am J Kidney Dis 2016; 67(5): 728 - 41. doi: 10.1053/j.ajkd.2015.10.011

196. Wu HY, Huang JW, Lin HJ et al. Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis. BMJ 2013; 347: f6008. doi: 10.1136/bmj.f6008

197. Hou W, Lv J, Perkovic V et al. Effect of statin therapy on cardiovascular and renal outcomes in patients with chronic kidney disease: a systematic review and meta-analysis. Eur Heart J 2013; 34(24): 1807 - 17. doi: 10.1093/eurheartj/eht065

198. Chewcharat A, Takkavatakarn K, Isaranuwatchai S et al. Pleiotropic effects of antidiabetic agents on renal and cardiovascular outcomes: a meta-analysis of randomized controlled trials. Int Urol Nephrol 2020; 52(9): 1733 - 1745. doi: 10.1007/s11255-020-02520-z

199. Pei G, Tang Y, Tan L et al. Aerobic exercise in adults with chronic kidney disease (CKD): a meta-analysis. Int Urol Nephrol 2019; 51(10): 1787 - 1795. doi: 10.1007/s11255-019-02234-x

200. Zelniker TA, Wiviott SD, Raz I et al. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet 2019; 393(10166): 31 - 39. doi: 10.1016/S0140-6736(18)32590-X

201. Seidu S, Kunutsor SK, Cos X et al. SGLT2 inhibitors and renal outcomes in type 2 diabetes with or without renal impairment: A systematic review and meta-analysis. Prim Care Diabetes 2018; 12(3): 265 - 283. doi: 10.1016/j.pcd.2018.02.001

202. Toyama T, Neuen BL, Jun M et al. Effect of SGLT2 inhibitors on cardiovascular, renal and safety outcomes in patients with type 2 diabetes mellitus and chronic kidney disease: A systematic review and meta-analysis. Diabetes Obes Metab 2019; 21(5): 1237 - 1250. doi: 10.1111/dom.13648

203. Feng C, Wu M, Chen Z et al. Effect of SGLT2 inhibitor on renal function in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of randomized controlled trials. Int Urol Nephrol 2019; 51(4): 655 - 669. doi: 10.1007/s11255-019-02112-6

204. Magee GM, Bilous RW, Cardwell CR et al. Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 2009; 52(4): 691 - 7. doi: 10.1007/s00125-009-1268-0

205. Yan B, Su X, Xu B et al. Effect of diet protein restriction on progression of chronic kidney disease: A systematic review and meta-analysis. PLoS One 2018; 13(11): e0206134. doi: 10.1371/journal.pone.0206134

206. Zhang L, Wang Y, Xiong L et al. Exercise therapy improves eGFR, and reduces blood pressure and BMI in non-dialysis CKD patients: evidence from a meta-analysis. BMC Nephrol 2019; 20(1): 398. doi: 10.1186/s12882-019-1586-5

207. Wu X, Yang L, Wang Y et al. Effects of combined aerobic and resistance exercise on renal function in adult patients with chronic kidney disease: a systematic review and meta-analysis. Clin Rehabil 2020; 34(7): 851 - 865. doi: 10.1177/0269215520924459

208. Heiwe S, Jacobson SH. Exercise training for adults with chronic kidney disease. Cochrane Database Syst Rev 2011; (10): CD003236. doi: 10.1002/14651858.CD003236.pub2

209. Bentata Y, Karimi I, Benabdellah N et al. Does smoking increase the risk of progression of nephropathy and/or cardiovascular disease in type 2 diabetic patients with albuminuria and those without albuminuria? Am J Cardiovasc Dis 2016; 6(2): 66 - 9

210. Grams ME, Yang W, Rebholz CM et al. Risks of Adverse Events in Advanced CKD: The Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2017; 70(3): 337 - 346. doi: 10.1053/j.ajkd.2017.01.050

211. Li K, Zou J, Ye Z et al. Effects of Bariatric Surgery on Renal Function in Obese Patients: A Systematic Review and Meta Analysis. PLoS One 2016; 11(10): e0163907. doi: 10.1371/journal.pone.0163907

212. Jicheng Lv, Perkovic V, Foote CV et al. Antihypertensive agents for preventing diabetic kidney disease. Cochrane Database Syst Rev 2012; 12: CD004136. doi: 10.1002/14651858.CD004136.pub3

213. Geng DF, Sun WF, Yang L et al. Antiproteinuric effect of angiotensin receptor blockers in normotensive patients with proteinuria: a meta-analysis of randomized controlled trials. J Renin Angiotensin Aldosterone Syst 2014; 15(1): 44 - 51. doi: 10.1177/1470320312474054

214. F, Saint-Gerons D, D et al. Cardiovascular and Renal Outcomes of Renin-Angiotensin System Blockade in Adult Patients with Diabetes Mellitus: A Systematic Review with Network Meta-Analyses. PLoS Med 2016; 13(3): e1001971. doi: 10.1371/journal.pmed.1001971

215. Hou FF, Xie D, Zhang X et al. Renoprotection of Optimal Antiproteinuric Doses (ROAD) Study: a randomized controlled study of benazepril and losartan in chronic renal insufficiency. J Am Soc Nephrol 2007; 18(6): 1889 - 98. doi: 10.1681/ASN.2006121372

216. Burgess E, Muirhead N, Rene de Cotret P et al. Supramaximal dose of candesartan in proteinuric renal disease. J Am Soc Nephrol 2009; 20(4): 893 - 900. doi: 10.1681/ASN.2008040416

217. Ricardo AC, Anderson CA, Yang W et al. Healthy lifestyle and risk of kidney disease progression, atherosclerotic events, and death in CKD: findings from the Chronic Renal Insufficiency Cohort (CRIC) Study. Am J Kidney Dis 2015; 65(3): 412 - 24. doi: 10.1053/j.ajkd.2014.09.016

218. Liu Y, Ma X, Zheng J et al. Effects of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on cardiovascular events and residual renal function in dialysis patients: a meta-analysis of randomised controlled trials. BMC Nephrol 2017; 18(1): 206. doi: 10.1186/s12882-017-0605-7

219. Zhang L, Zeng X, Fu P, Wu HM. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers for preserving residual kidney function in peritoneal dialysis patients. Cochrane Database Syst Rev 2014; (6): CD009120. doi: 10.1002/14651858.CD009120.pub2

220. Tian ML, Shen Y, Sun ZL, Zha Y. Efficacy and safety of combining pentoxifylline with angiotensin-converting enzyme inhibitor or angiotensin II receptor blocker in diabetic nephropathy: a meta-analysis. Int Urol Nephrol 2015; 47(5): 815 - 22. doi: 10.1007/s11255-015-0968-2

221. Liu D, Wang LN, Li HX et al. Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis. J Int Med Res 2017; 45(2): 383 - 398. doi: 10.1177/0300060516663094

222. JF, C, Muros de Fuentes M et al. Effect of pentoxifylline on renal function and urinary albumin excretion in patients with diabetic kidney disease: the PREDIAN trial. J Am Soc Nephrol 2015; 26(1): 220 - 229. doi: 10.1681/ASN.2014010012

223. Ghorbani A, Omidvar B, Beladi-Mousavi SS et al. The effect of pentoxifylline on reduction of proteinuria among patients with type 2 diabetes under blockade of angiotensin system: a double blind and randomized clinical trial. Nefrologia 2012; 32(6): 790 - 796. doi: 10.3265/Nefrologia.pre2012.Jun.11242

224. Renke M, Tylicki L, Rutkowski P et al. Effect of pentoxifylline on proteinuria, markers of tubular injury and oxidative stress in non-diabetic patients with chronic kidney disease - placebo controlled, randomized, cross-over study. Acta Biochim Pol 2010; 57(1): 119 - 123

225. Oliaei F, Hushmand S, Khafri S et al. Efficacy of pentoxifylline for reduction of proteinuria in type II diabetic patients. Caspian J Intern Med 2011; 2: 309 - 313

226. Lin SL, Chen YM, Chiang WC et al. Effect of pentoxifylline in addition to losartan on proteinuria and GFR in CKD: a 12-month randomized trial. Am J Kidney Dis 2008; 52(3): 464 - 474. doi: 10.1053/j.ajkd.2008.05.012

227. Navarro JF, Mora C, Muros M et al. Effects of pentoxifylline administration on urinary N-acetyl-beta-glucosaminidase excretion in type 2 diabetic patients: a short-term, prospective, randomized study. Am J Kidney Dis 2003; 42(2): 264 - 270. doi: 10.1016/s0272-6386(03)00651-6

228. Roozbeh J, Banihashemi MA, Ghezlou M et al. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy. Ren Fail 2010; 32(2): 172 - 178. doi: 10.3109/08860221003602645

229. Perkins RM, Aboudara MC, Uy AL et al. Effect of pentoxifylline on GFR decline in CKD: a pilot, double-blind, randomized, placebo-controlled trial. Am J Kidney Dis 2009; 53(4): 606 - 616. doi: 10.1053/j.ajkd.2008.11.026

230. Harmankaya O, Seber S, Yilmaz M. Combination of pentoxifylline with angiotensin converting enzyme inhibitors produces an additional reduction in microalbuminuria in hypertensive type 2 diabetic patients. Ren Fail 2003; 25(3): 465 - 470. doi: 10.1081/jdi-120021159

231. Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M et al. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011; 343: d4169. doi: 10.1136/bmj.d4169

232. Hemmingsen B, Lund SS, Gluud C et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2013; (11): CD008143. doi: 10.1002/14651858.CD008143.pub3

233. Ismail-Beigi F, Craven T, Banerji MA et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomised trial. Lancet 2010; 376(9739): 419 - 30. doi: 10.1016/S0140-6736(10)60576-4

234. Сахарный диабет 2 типа у взрослых. Клинические рекомендации. https://cr.minzdrav.gov.ru/schema/290_2

235. Qiu M, Ding LL, Wei XB et al. Comparative efficacy of GLP-1 RAs and SGLT2is for prevention of major adverse cardiovascular events in type 2 diabetes: a network meta-analysis. J Cardiovasc Pharmacol 2020 Oct 22. doi: 10.1097/FJC.0000000000000916. Online ahead of print

236. Kristensen SL, R, Jhund PS et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 2019; 7(10): 776 - 785. doi: 10.1016/S2213-8587(19)30249-9

237. Agarwal R, Filippatos G, Pitt B et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J 2022; 43(6): 474 - 484. doi: 10.1093/eurheartj/ehab777

238. Shi Q, Nong K, Vandvik PO et al. Benefits and harms of drug treatment for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. BMJ 2023; 381: e074068. doi: 10.1136/bmj-2022-074068

239. Zhang Y, Jiang L, Wang J et al. Network meta-analysis on the effects of finerenone versus SGLT2 inhibitors and GLP-1 receptor agonists on cardiovascular and renal outcomes in patients with type 2 diabetes mellitus and chronic kidney disease. Cardiovasc Diabetol 2022; 21(1): 232. doi: 10.1186/s12933-022-01676-5

240. Gu X, Jiang S, Yang Y, Li W. Effects of finerenone and glucagon-like peptide 1 receptor agonists on cardiovascular and renal outcomes in type 2 diabetes mellitus: a systematic review and meta-analysis. Diabetol Metab Syndr 2024; 16(1): 14. doi: 10.1186/s13098-023-01251-2

241. DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial. Lancet Diabetes Endocrinol 2021; 9(1): 22 - 31. doi: 10.1016/S2213-8587(20)30369-7

242. Nuffield Department of Population Health Renal Studies Group; SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists" Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet 2022; 400(10365): 1788 - 1801. doi: 10.1016/S0140-6736(22)02074-8

243. Tsai WC, Hsu SP, Chiu YL et al. Cardiovascular and renal efficacy and safety of sodium-glucose cotransporter-2 inhibitors in patients without diabetes: a systematic review and meta-analysis of randomised placebo-controlled trials. BMJ Open. 2022; 12(10): e060655. doi: 10.1136/bmjopen-2021-060655

244. Ettehad D, Emdin CA, Kiran A et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 2016; 387(10022): 95 - 967. doi: 10.1016/S0140-6736(15)01225-8

245. Aggarwal R, Petrie B, Bala W, Chiu N. Mortality Outcomes With Intensive Blood Pressure Targets in Chronic Kidney Disease Patients. Hypertension 2019; 73(6): 1275 - 1282. doi: 10.1161/HYPERTENSIONAHA.119.12697

246. Tsai WC, Wu HY, Peng YS et al. Association of Intensive Blood Pressure Control and Kidney Disease Progression in Nondiabetic Patients With Chronic Kidney Disease: A Systematic Review and Meta-analysis. JAMA Intern Med 2017; 177(6): 792 - 799. doi: 10.1001/jamainternmed.2017.0197

247. Ku E, Sarnak MJ, Toto R et al. Effect of Blood Pressure Control on Long-Term Risk of End-Stage Renal Disease and Death Among Subgroups of Patients With Chronic Kidney Disease. J Am Heart Assoc 2019; 8(16): e012749. doi: 10.1161/JAHA.119.012749

248. Beddhu S, Greene T, Boucher R et al. Intensive systolic blood pressure control and incident chronic kidney disease in people with and without diabetes mellitus: secondary analyses of two randomised controlled trials. Lancet Diabetes Endocrinol 2018; 6(7): 555 - 563. doi: 10.1016/S2213-8587(18)30099-8

249. Rocco MV, Sink KM, Lovato LC et al. Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT). Am J Kidney Dis 2018; 71(3): 352 - 361. doi: 10.1053/j.ajkd.2017.08.021

250. Chi G, Jamil A, Jamil U et al. Effect of intensive versus standard blood pressure control on major adverse cardiac events and serious adverse events: A bivariate analysis of randomized controlled trials. Clin Exp Hypertens 2018; 1 - 8. doi: 10.1080/10641963.2018.1462373

251. SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015; 373(22): 2103 - 16. doi: 10.1056/NEJMoa1511939

252. Huang RS, Cheng YM, Zeng XX et al. Renoprotective Effect of the Combination of Renin-angiotensin System Inhibitor and Calcium Channel Blocker in Patients with Hypertension and Chronic Kidney Disease. Chin Med J (Engl) 2016; 129(5): 562 - 9. doi: 10.4103/0366-6999.176987

253. Thamcharoen N, Susantitaphong P, Wongrakpanich S et al. Effect of N- and T-type calcium channel blocker on proteinuria, blood pressure and kidney function in hypertensive patients: a meta-analysis. Hypertens Res 2015; 38(12): 847 - 55. doi: 10.1038/hr.2015.69

254. Kario K, Tomitani N, Kanegae H et al. Comparative Effects of an Angiotensin II Receptor Blocker (ARB)/Diuretic vs. ARB/Calcium-Channel Blocker Combination on Uncontrolled Nocturnal Hypertension Evaluated by Information and Communication Technology-Based Nocturnal Home Blood Pressure Monitoring - The NOCTURNE Study. Circ J 2017; 81(7): 948 - 957. doi: 10.1253/circj.CJ-17-0109

255. Zhao HJ, Li Y, Liu SM et al. Effect of calcium channels blockers and inhibitors of the renin-angiotensin system on renal outcomes and mortality in patients suffering from chronic kidney disease: systematic review and meta-analysis. Ren Fail 2016; 38(6): 849 - 56. doi: 10.3109/0886022X.2016.1165065

256. Lin YC, Lin JW, Wu MS et al. Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: A systematic review and meta-analysis. PLoS One 2017; 12(12): e0188975. doi: 10.1371/journal.pone.0188975

257. Pongpanich P, Pitakpaiboonkul P, Takkavatakarn K et al. The benefits of angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers combined with calcium channel blockers on metabolic, renal, and cardiovascular outcomes in hypertensive patients: a meta-analysis. Int Urol Nephrol 2018; 50(12): 2261 - 2278. doi: 10.1007/s11255-018-1991-x

258. DM, Visser WJ, Middel I et al. A Randomized Trial of Distal Diuretics versus Dietary Sodium Restriction for Hypertension in Chronic Kidney Disease. J Am Soc Nephrol 2020; 31(3): 650 - 662. doi: 10.1681/ASN.2019090905

259. Heerspink HJ, Ninomiya T, Perkovic V et al. Effects of a fixed combination of perindopril and indapamide in patients with type 2 diabetes and chronic kidney disease. Eur Heart J 2010; 31(23): 2888 - 96. doi: 10.1093/eurheartj/ehq139

260. Abe M, Okada K, Maruyama T, Matsumoto K. Antiproteinuric and blood pressure-lowering effects of a fixed-dose combination of losartan and hydrochlorothiazide in hypertensive patients with stage 3 chronic kidney disease. Pharmacotherapy 2009; 29(9): 1061 - 72. doi: 10.1592/phco.29.9.1061

261. Ando K, Nitta K, Rakugi H et al. Comparison of the antialbuminuric effects of benidipine and hydrochlorothiazide in Renin-Angiotensin System (RAS) inhibitor-treated hypertensive patients with albuminuria: the COSMO-CKD (COmbination Strategy on Renal Function of Benidipine or Diuretics TreatMent with RAS inhibitOrs in a Chronic Kidney Disease Hypertensive Population) study. Int J Med Sci 2014; 11(9): 897 - 904. doi: 10.7150/ijms.9026

262. Cheng Y, Huang R, Kim S et al. Renoprotective effects of renin-angiotensin system inhibitor combined with calcium channel blocker or diuretic in hypertensive patients: A PRISMA-compliant meta-analysis. Medicine (Baltimore) 2016; 95(28): e4167. doi: 10.1097/MD.0000000000004167

263. Vasavada N, Saha C, Agarwal R. A double-blind randomized crossover trial of two loop diuretics in chronic kidney disease. Kidney Int 2003; 64(2): 632 - 40. doi: 10.1046/j.1523-1755.2003.00124.x

264. Mourad G, Haecker W, Mion C. Dose-dependent salidiuretic efficacy of torasemide in comparison to furosemide and placebo in advanced renal failure. Arzneimittelforschung 1988; 38(1A): 205 - 8

265. Dussol B, Moussi-Frances J, Morange S et al. A pilot study comparing furosemide and hydrochlorothiazide in patients with hypertension and stage 4 or 5 chronic kidney disease. J Clin Hypertens (Greenwich) 2012; 14(1): 32 - 7. doi: 10.1111/j.1751-7176.2011.00564.x

266. Khan YH, Sarriff A, Adnan AS et al. Chronic Kidney Disease, Fluid Overload and Diuretics: A Complicated Triangle. PLoS One 2016; 11(7): e0159335. doi: 10.1371/journal.pone.0159335

267. Zhang X, Zhao Q. Association of Thiazide-Type Diuretics With Glycemic Changes in Hypertensive Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials. J Clin Hypertens (Greenwich) 2016; 18(4): 342 - 51. doi: 10.1111/jch.12679

268. Hall JJ, Eurich DT, Nagy D et al. Thiazide Diuretic-Induced Change in Fasting Plasma Glucose: a Meta-analysis of Randomized Clinical Trials. J Gen Intern Med 2020; 35(6): 1849 - 1860. doi: 10.1007/s11606-020-05731-3

269. Bolignano D, Palmer SC, Navaneethan SD, Strippoli GF. Aldosterone antagonists for preventing the progression of chronic kidney disease. Cochrane Database Syst Rev 2014; (4): CD007004. doi: 10.1002/14651858.CD007004.pub3

270. Alexandrou ME, Papagianni A, Tsapas A et al. Effects of mineralocorticoid receptor antagonists in proteinuric kidney disease: a systematic review and meta-analysis of randomized controlled trials. J Hypertens 2019; 37(12): 2307 - 2324. doi: 10.1097/HJH.0000000000002187

271. Currie G, Taylor AH, Fujita T et al. Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis. BMC Nephrol 2016 Sep 8; 17(1): 127. doi: 10.1186/s12882-016-0337-0

272. Ferreira JP, Pitt B, McMurray JJV et al. Steroidal MRA Across the Spectrum of Renal Function: A Pooled Analysis of RCTs. JACC Heart Fail 2022; 10(11): 842 - 850. doi: 10.1016/j.jchf.2022.06.010

273. Li Y, Xie N, Liang M. Aldosterone Antagonists Reduce the Risk of Cardiovascular Mortality in Dialysis Patients: A Meta-Analysis. Evid Based Complement Alternat Med 2019; 2019: 1925243. doi: 10.1155/2019/1925243

274. Quach K, Lvtvyn L, Baigent C et al. The Safety and Efficacy of Mineralocorticoid Receptor Antagonists in Patients Who Require Dialysis: A Systematic Review and Meta-analysis. Am J Kidney Dis 2016; 68(4): 591 - 598. doi: 10.1053/j.ajkd.2016.04.011

275. Matsumoto Y, Mori Y, Kageyama S et al. Spironolactone reduces cardiovascular and cerebrovascular morbidity and mortality in hemodialysis patients. J Am Coll Cardiol 2014; 63(6): 528 - 36. doi: 10.1016/j.jacc.2013.09.056

276. Ito Y, Mizuno M, Suzuki Y et al. Long-term effects of spironolactone in peritoneal dialysis patients. J Am Soc Nephrol 2014; 25(5): 1094 - 102. doi: 10.1681/ASN.2013030273

277. Lin C, Zhang Q, Zhang H, Lin A. Long-Term Effects of Low-Dose Spironolactone on Chronic Dialysis Patients: A Randomized Placebo-Controlled Study. J Clin Hypertens (Greenwich) 2016; 18(2): 121 - 8. doi: 10.1111/jch.12628

278. Feniman-De-Stefano GM, Zanati-Basan SG, De Stefano LM et al. Spironolactone is secure and reduces left ventricular hypertrophy in hemodialysis patients. Ther Adv Cardiovasc Dis 2015; 9(4): 158 - 67. doi: 10.1177/1753944715591448

279. Walsh M, Manns B, Garg AX et al. The Safety of Eplerenone in Hemodialysis Patients: A Noninferiority Randomized Controlled Trial. Clin J Am Soc Nephrol 2015; 10(9): 1602 - 8. doi: 10.2215/CJN.12371214

280. Flevari P, Kalogeropoulou S, Drakou A et al. Spironolactone improves endothelial and cardiac autonomic function in non heart failure hemodialysis patients. J Hypertens 2013; 31(6): 1239 - 44. doi: 10.1097/HJH.0b013e32835f955c

281. Di Iorio BR, Bellasi A, Raphael KL et al. Treatment of metabolic acidosis with sodium bicarbonate delays progression of chronic kidney disease: the UBI Study. J Nephrol 2019; 32(6): 989 - 1001. doi: 10.1007/s40620-019-00656-5

282. Sampson AL, Singer RF, Walters GD. Uric acid lowering therapies for preventing or delaying the progression of chronic kidney disease. Cochrane Database Syst Rev 2017; 10(10): CD009460. doi: 10.1002/14651858.CD009460.pub2

283. Kovesdy CP, Matsushita K, Sang Y et al. Serum potassium and adverse outcomes across the range of kidney function: a CKD Prognosis Consortium meta-analysis. Eur Heart J 2018; 39(17): 1535 - 1542. doi: 10.1093/eurheartj/ehy100

284. Zhang Y, Chen P, Chen J et al. Association of Low Serum Potassium Levels and Risk for All-Cause Mortality in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. Ther Apher Dial 2019 Feb; 23(1): 22 - 31. doi: 10.1111/1744-9987.12753

285. Cowan AC, Gharib EG, Weir MA. Advances in the management of hyperkalemia in chronic kidney disease. Curr Opin Nephrol Hypertens 2017; 26(3): 235 - 239. doi: 10.1097/MNH.0000000000000320

286. Clase CM, Carrero JJ, Ellison DH et al. Potassium homeostasis and management of dyskalemia in kidney diseases: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney Int 2020; 97(1): 42 - 61. doi: 10.1016/j.kint.2019.09.018

287. Gritter M, Vogt L, Yeung SMH et al. Rationale and Design of a Randomized Placebo-Controlled Clinical Trial Assessing the Renoprotective Effects of Potassium Supplementation in Chronic Kidney Disease. Nephron 2018; 140(1): 48 - 57. doi: 10.1159/000490261

288. Morris A, Krishnan N, Kimani PK, Lycett D. Effect of Dietary Potassium Restriction on Serum Potassium, Disease Progression, and Mortality in Chronic Kidney Disease: A Systematic Review and Meta-Analysis. J Ren Nutr 2020; 30(4): 276 - 285. doi: 10.1053/j.jrn.2019.09.009

289. Kalantar-Zadeh K, Fouque D. Nutritional Management of Chronic Kidney Disease. N Engl J Med 2017; 377(18): 1765 - 1776. doi: 10.1056/NEJMra1700312

290. Kashihara N, Kohsaka S, Kanda E et al. Hyperkalemia in Real-World Patients Under Continuous Medical Care in Japan. Kidney Int Rep 2019; 4(9): 1248 - 1260. doi: 10.1016/j.ekir.2019.05.018

291. Palmer BF, Clegg DJ. Treatment of Abnormalities of Potassium Homeostasis in CKD. Adv Chronic Kidney Dis 2017; 24(5): 319 - 324. doi: 10.1053/j.ackd.2017.06.001

292. Mahoney BA, Smith WA, Lo DS et al. Emergency interventions for hyperkalaemia. Cochrane Database Syst Rev 2005; 2005(2): CD003235. doi: 10.1002/14651858.CD003235.pub2

293. Liou HH, Chiang SS, Wu SC et al. Intravenous infusion or nebulization of salbutamol for treatment of hyperkalemia in patients with chronic renal failure. Zhonghua Yi Xue Za Zhi (Taipei) 1994; 53(5): 276 - 81

294. Mandelberg A, Krupnik Z, Houri S et al. Salbutamol metered-dose inhaler with spacer for hyperkalemia: how fast? How safe? Chest 1999; 115(3): 617 - 22. doi: 10.1378/chest.115.3.617

295. Allon M, Copkney C. Albuterol and insulin for treatment of hyperkalemia in hemodialysis patients. Kidney International 1990; 38(5): 869 - 72. doi: 10.1038/ki.1990.284

296. Moussavi K, Nguyen LT, Hua H, Fitter S. Comparison of IV Insulin Dosing Strategies for Hyperkalemia in the Emergency Department. Crit Care Explor 2020; 2(4): e0092. doi: 10.1097/CCE.0000000000000092

297. Harel Z, Kamel KS. Optimal Dose and Method of Administration of Intravenous Insulin in the Management of Emergency Hyperkalemia: A Systematic Review. PLoS One 2016; 11(5): e0154963. doi: 10.1371/journal.pone.0154963

298. Moussavi K, Fitter S, Gabrielson SW et al. Management of Hyperkalemia With Insulin and Glucose: Pearls for the Emergency Clinician. J Emerg Med 2019; 57(1): 36 - 42. doi: 10.1016/j.jemermed.2019.03.043

299. A, Deakin CD, Soar J et al. European Resuscitation Council Guidelines for Resuscitation 2015: Section 4. Cardiac arrest in special circumstances. Resuscitation 2015; 95: 148 - 201. doi: 10.1016/j.resuscitation.2015.07.017

300. Suki WN. Use of diuretics in chronic renal failure. Kidney Int Suppl 1997; 59: S33 - 5

301. Lepage L, Dufour AC, Doiron J et al. Randomized Clinical Trial of Sodium Polystyrene Sulfonate for the Treatment of Mild Hyperkalemia in CKD. Clin J Am Soc Nephrol 2015; 10(12): 2136 - 42. doi: 10.2215/CJN.03640415

302. Wang J, Lv MM, Zach O et al. Calcium-Polystyrene Sulfonate Decreases Inter-Dialytic Hyperkalemia in Patients Undergoing Maintenance Hemodialysis: A Prospective, Randomized, Crossover Study. Ther Apher Dial 2018; 22(6): 609 - 616. doi: 10.1111/1744-9987.12723

303. de Brito-Ashurst I, Varagunam M, Raftery MJ, Yaqoob MM. Bicarbonate supplementation slows progression of CKD and improves nutritional status. J Am Soc Nephrol 2009; 20(9): 2075 - 84. doi: 10.1681/ASN.2008111205

304. Mahajan A, Simoni J, Sheather SJ et al. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 2010; 78(3): 303 - 9. doi: 10.1038/ki.2010.129

305. Dubey AK, Sahoo J, Vairappan B et al. Correction of metabolic acidosis improves muscle mass and renal function in chronic kidney disease stages 3 and 4: a randomized controlled trial. Nephrol Dial Transplant 2020; 35(1): 121 - 129. doi: 10.1093/ndt/gfy214

306. Sodium Bicarbonate Dosage. https://www.drugs.com/dosage/sodium-bicarbonate.html

307. Cholesterol Treatment Trialists" (CTT) Collaboration. Impact of renal function on the effects of LDL cholesterol lowering with statin-based regimens: a meta-analysis of individual participant data from 28 randomised trials. Lancet Diabetes Endocrinol 2016; 4(10): 829 - 39. doi: 10.1016/S2213-8587(16)30156-5

308. Navaneethan SD, Pansini F, Perkovic V et al. HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. Cochrane Database Syst Rev 2009; (2): CD007784. doi: 10.1002/14651858.CD007784

309. Sanguankeo A, Upala S, Cheungpasitporn W et al. Effects of Statins on Renal Outcome in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. PLoS One 2015; 10(7): e0132970. doi: 10.1371/journal.pone.0132970

310. Barylski M, Nikfar S, Mikhailidis DP et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta-analysis of 11 randomized controlled trials involving 21,295 participants. Pharmacol Res 2013; 72: 35 - 44. doi: 10.1016/j.phrs.2013.03.007

311. Silbernagel G, Fauler G, Genser B et al. Intestinal cholesterol absorption, treatment with atorvastatin, and cardiovascular risk in hemodialysis patients. J Am Coll Cardiol 2015; 65(21): 2291 - 8. doi: 10.1016/j.jacc.2015.03.551

312. Liao G, Wang X, Li Y et al. Antidyslipidemia Pharmacotherapy in Chronic Kidney Disease: A Systematic Review and Bayesian Network Meta-Analysis. Pharmaceutics 2022; 15(1): 6. doi: 10.3390/pharmaceutics15010006

313. Charytan DM, Sabatine MS, Pedersen TR et al. Efficacy and Safety of Evolocumab in Chronic Kidney Disease in the FOURIER Trial. J Am Coll Cardiol 2019; 73(23): 2961 - 2970. doi: 10.1016/j.jacc.2019.03.513

314. J, Steg PG, Bhatt DL et al. Effect of alirocumab on major adverse cardiovascular events according to renal function in patients with a recent acute coronary syndrome: prespecified analysis from the ODYSSEY OUTCOMES randomized clinical trial. Eur Heart J 2020; 41(42): 4114 - 4123. doi: 10.1093/eurheartj/ehaa498

315. Koenig W, Conde LG, Landmesser U et al. Efficacy and Safety of Inclisiran in Patients with Polyvascular Disease: Pooled, Post Hoc Analysis of the ORION-9, ORION-10, and ORION-11 Phase 3 Randomized Controlled Trials. Cardiovasc Drugs Ther 2024; 38(3): 493 - 503. doi: 10.1007/s10557-022-07413-0

316. Rhee CM, Ahmadi SF, Kovesdy CP, Kalantar-Zadeh K. Low-protein diet for conservative management of chronic kidney disease: a systematic review and meta-analysis of controlled trials. J Cachexia Sarcopenia Muscle 2018; 9(2): 235 - 245. doi: 10.1002/jcsm.12264

317. Hahn D, Hodson EM, Fouque D. Low protein diets for non-diabetic adults with chronic kidney disease. Cochrane Database Syst Rev 2018; 10(10): CD001892. doi: 10.1002/14651858.CD001892.pub4

318. Jing Z, Wei-Jie Y. Effects of soy protein containing isoflavones in patients with chronic kidney disease: A systematic review and meta-analysis. Clin Nutr 2016; 35(1): 117 - 124. doi: 10.1016/j.clnu.2015.03.012

319. Zhang J, Liu J, Su J, Tian F. The effects of soy protein on chronic kidney disease: a meta-analysis of randomized controlled trials. Eur J Clin Nutr 2014; 68(9): 987 - 93. doi: 10.1038/ejcn.2014.112

320. Anderson JW, Bush HM. Soy protein effects on serum lipoproteins: a quality assessment and meta-analysis of randomized, controlled studies. J Am Coll Nutr 2011; 30(2): 79 - 91. doi: 10.1080/07315724.2011.10719947

321. Di Iorio BR, Rocchetti MT, De Angelis M et al. Nutritional Therapy Modulates Intestinal Microbiota and Reduces Serum Levels of Total and Free Indoxyl Sulfate and P-Cresyl Sulfate in Chronic Kidney Disease (Medika Study). J Clin Med 2019; 8(9): 1424. doi: 10.3390/jcm8091424

322. Li A, Lee HY, Lin YC. The Effect of Ketoanalogues on Chronic Kidney Disease Deterioration: A Meta-Analysis. Nutrients 2019; 11(5): 957. doi: 10.3390/nu11050957

323. Chewcharat A, Takkavatakarn K, Wongrattanagorn S et al. The Effects of Restricted Protein Diet Supplemented With Ketoanalogue on Renal Function, Blood Pressure, Nutritional Status, and Chronic Kidney Disease-Mineral and Bone Disorder in Chronic Kidney Disease Patients: A Systematic Review and Meta-Analysis. J Ren Nutr 2020; 30(3): 189 - 199. doi: 10.1053/j.jrn.2019.07.005

324. Jiang Z, Zhang X, Yang L, Li Z, Qin W. Effect of restricted protein diet supplemented with keto analogues in chronic kidney disease: a systematic review and meta-analysis. Int Urol Nephrol 2016; 48(3): 409 - 18. doi: 10.1007/s11255-015-1170-2

325. Jiang Z, Tang Y, Yang L et al. Effect of restricted protein diet supplemented with keto analogues in end-stage renal disease: a systematic review and meta-analysis. Int Urol Nephrol 2018; 50(4): 687 - 694. doi: 10.1007/s11255-017-1713-9

326. Palmer SC, Hayen A, Macaskill P et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 2011; 305(11): 1119 - 27. doi: 10.1001/jama.2011.308

327. Block GA, Wheeler DC, Persky MS et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23(8): 1407 - 15. doi: 10.1681/ASN.2012030223

328. Moe SM, Zidehsarai MP, Chambers MA et al. Vegetarian compared with meat dietary protein source and phosphorus homeostasis in chronic kidney disease. Clin J Am Soc Nephrol 2011; 6(2): 257 - 64. doi: 10.2215/CJN.05040610

329. Sigrist M, Tang M, Beaulieu M et al. Responsiveness of FGF-23 and mineral metabolism to altered dietary phosphate intake in chronic kidney disease (CKD): results of a randomized trial. Nephrol Dial Transplant 2013; 28(1): 161 - 9. doi: 10.1093/ndt/gfs405

330. Chang AR, Miller ER 3rd, Anderson CA et al. Phosphorus Additives and Albuminuria in Early Stages of CKD: A Randomized Controlled Trial. Am J Kidney Dis 2017; 69(2): 200 - 209. doi: 10.1053/j.ajkd.2016.08.029

331. Pisani A, Riccio E, Bellizzi V et al. 6-tips diet: a simplified dietary approach in patients with chronic renal disease. A clinical randomized trial. Clin Exp Nephrol 2016; 20(3): 433 - 42. doi: 10.1007/s10157-015-1172-5

332. Garneata L, Stancu A, Dragomir D et al. Ketoanalogue-Supplemented Vegetarian Very Low-Protein Diet and CKD Progression. J Am Soc Nephrol 2016; 27(7): 2164 - 76. doi: 10.1681/ASN.2015040369

333. de Fornasari ML, Dos Santos Sens YA. Replacing Phosphorus-Containing Food Additives With Foods Without Additives Reduces Phosphatemia in End-Stage Renal Disease Patients: A Randomized Clinical Trial. J Ren Nutr 2017; 27(2): 97 - 105. doi: 10.1053/j.jrn.2016.08.009

334. Lou LM, Caverni A, Gimeno JA et al. Dietary intervention focused on phosphate intake in hemodialysis patients with hyperphosphoremia. Clin Nephrol 2012; 77(6): 476 - 83

335. Sullivan C, Sayre SS, Leon JB et al. Effect of food additives on hyperphosphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 2009; 301(6): 629 - 35. doi: 10.1001/jama.2009.96

336. Murali KM, Mullan J, Roodenrys S et al. Strategies to improve dietary, fluid, dialysis or medication adherence in patients with end stage kidney disease on dialysis: A systematic review and meta-analysis of randomized intervention trials. PLoS One 2019; 14(1): e0211479. doi: 10.1371/journal.pone.0211479

337. Caldeira D, Amaral T, David C, Sampaio C. Educational strategies to reduce serum phosphorus in hyperphosphatemic patients with chronic kidney disease: systematic review with meta-analysis. J Ren Nutr 2011; 21(4): 285 - 94. doi: 10.1053/j.jrn.2010.11.006

338. Shi Y, Zhao Y, Liu J et al. Educational intervention for metabolic bone disease in patients with chronic kidney disease: a systematic review and meta-analysis. J Ren Nutr 2014; 24(6): 371 - 84. doi: 10.1053/j.jrn.2014.06.007

339. Milazi M, Bonner A, Douglas C. Effectiveness of educational or behavioral interventions on adherence to phosphate control in adults receiving hemodialysis: a systematic review. JBI Database System Rev Implement Rep 2017; 15(4): 971 - 1010. doi: 10.11124/JBISRIR-2017-003360

340. Karavetian M, de Vries N, Rizk R, Elzein H. Dietary educational interventions for management of hyperphosphatemia in hemodialysis patients: a systematic review and meta-analysis. Nutr Rev 2014; 72(7): 471 - 82. doi: 10.1111/nure.12115

341. Daugirdas JT, Chertow GM, Larive B et al. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol 2012; 23(4): 727 - 38. doi: 10.1681/ASN.2011070688

342. Zimmerman DL, Nesrallah GE, Chan CT et al. Dialysate calcium concentration and mineral metabolism in long and long-frequent hemodialysis: a systematic review and meta-analysis for a Canadian Society of Nephrology clinical practice guideline. Am J Kidney Dis 2013; 62(1): 97 - 111. doi: 10.1053/j.ajkd.2013.02.357

343. Cornelis T, van der Sande FM, Eloot S et al. Acute hemodynamic response and uremic toxin removal in conventional and extended hemodialysis and hemodiafiltration: a randomized crossover study. Am J Kidney Dis 2014; 64(2): 247 - 56. doi: 10.1053/j.ajkd.2014.02.016

344. Walsh M, Manns BJ, Klarenbach S et al. The effects of nocturnal compared with conventional hemodialysis on mineral metabolism: A randomized-controlled trial. Hemodial Int 2010; 14(2): 174 - 81. doi: 10.1111/j.1542-4758.2009.00418.x

345. Culleton BF, Walsh M, Klarenbach SW et al. Effect of frequent nocturnal hemodialysis vs conventional hemodialysis on left ventricular mass and quality of life: a randomized controlled trial. JAMA 2007; 298(11): 1291 - 9. doi: 10.1001/jama.298.11.1291

346. Gutzwiller JP, Schneditz D, Huber AR et al. Increasing blood flow increases kt/V(urea) and potassium removal but fails to improve phosphate removal. Clin Nephrol 2003; 59(2): 130 - 6. doi: 10.5414/cnp59130

347. Vaithilingam I, Polkinghorne KR, Atkins RC, Kerr PG. Time and exercise improve phosphate removal in hemodialysis patients. Am J Kidney Dis 2004; 43(1): 85 - 9. doi: 10.1053/j.ajkd.2003.09.016

348. Gutzwiller JP, Schneditz D, Huber AR et al. Estimating phosphate removal in haemodialysis: an additional tool to quantify dialysis dose. Nephrol Dial Transplant 2002; 17(6): 1037 - 44. doi: 10.1093/ndt/17.6.1037

349. Cupisti A, Gallieni M, Rizzo MA et al. Phosphate control in dialysis. Int J Nephrol Renovasc Dis 2013; 6: 193 - 205. doi: 10.2147/IJNRD.S35632

350. Sampaio MS, Ruzany F, Dorigo DM, Suassuna JH. Phosphate mass removal during hemodialysis: a comparison between eKT/V-matched conventional and extended dialysis. Am J Nephrol 2012; 36(2): 121 - 6. doi: 10.1159/000338675

351. T, Ponikvar R, J, J. Phosphate Removal During Long Nocturnal Hemodialysis/Hemodiafiltration: A Study With Total Dialysate Collection. Ther Apher Dial 2016; 20(3): 267 - 71. doi: 10.1111/1744-9987.12435

352. Ayus JC, Mizani MR, Achinger SG et al. Effects of short daily versus conventional hemodialysis on left ventricular hypertrophy and inflammatory markers: a prospective, controlled study. J Am Soc Nephrol 2005; 16(9): 2778 - 88. doi: 10.1681/ASN.2005040392

353. Susantitaphong P, Siribamrungwong M, Jaber BL. Convective therapies versus low-flux hemodialysis for chronic kidney failure: a meta-analysis of randomized controlled trials. Nephrol Dial Transplant 2013; 28(11): 2859 - 74. doi: 10.1093/ndt/gft396

354. INDEPENDENT Study Investigators. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012; 7(3): 487 - 93. doi: 10.2215/CJN.03820411

355. Ruospo M, Palmer SC, Natale P et al. Phosphate binders for preventing and treating chronic kidney disease-mineral and bone disorder (CKD-MBD). Cochrane Database Syst Rev 2018; 8(8): CD006023. doi: 10.1002/14651858.CD006023.pub3

356. Lioufas NM, Pascoe EM, Hawley CM et al. Systematic Review and Meta-Analyses of the Effects of Phosphate-Lowering Agents in Nondialysis CKD. J Am Soc Nephrol 2022; 33(1): 59 - 76. doi: 10.1681/ASN.2021040554

357. Habbous S, Przech S, Acedillo R et al. The efficacy and safety of sevelamer and lanthanum versus calcium-containing and iron-based binders in treating hyperphosphatemia in patients with chronic kidney disease: a systematic review and meta-analysis. Nephrol Dial Transplant 2017; 32(1): 111 - 125. doi: 10.1093/ndt/gfw312

358. Jamal SA, Vandermeer B, Raggi P et al. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet 2013; 382(9900): 1268 - 77. doi: 10.1016/S0140-6736(13)60897-1

359. Sekercioglu N, Thabane L, JP et al. Comparative Effectiveness of Phosphate Binders in Patients with Chronic Kidney Disease: A Systematic Review and Network Meta-Analysis. PLoS One 2016; 11(6): e0156891. doi: 10.1371/journal.pone.0156891

360. Patel L, Bernard LM, Elder GJ. Sevelamer Versus Calcium-Based Binders for Treatment of Hyperphosphatemia in CKD: A Meta-Analysis of Randomized Controlled Trials. Clin J Am Soc Nephrol 2016; 11(2): 232 - 44. doi: 10.2215/CJN.06800615

361. Hill KM, Martin BR, Wastney ME et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3 - 4 chronic kidney disease. Kidney Int 2013; 83(5): 959 - 66. doi: 10.1038/ki.2012.403

362. Wang F, Lu X, Zhang J et al. Effect of Lanthanum Carbonate on All-Cause Mortality in Patients Receiving Maintenance Hemodialysis: a Meta-Analysis of Randomized Controlled Trials. Kidney Blood Press Res 2018; 43(2): 536 - 544. doi: 10.1159/000488700

363. Sekercioglu N, Angeliki Veroniki A, Thabane L et al. Effects of different phosphate lowering strategies in patients with CKD on laboratory outcomes: A systematic review and NMA. PLoS One 2017; 12(3): e0171028. doi: 10.1371/journal.pone.0171028

364. Geng S, Kuang Z, Peissig PL et al. Parathyroid hormone independently predicts fracture, vascular events, and death in patients with stage 3 and 4 chronic kidney disease. Osteoporos Int 2019; 30(10): 2019 - 2025. doi: 10.1007/s00198-019-05033-3

365. Shardlow A, McIntyre NJ, Fluck RJ et al. Associations of fibroblast growth factor 23, vitamin D and parathyroid hormone with 5-year outcomes in a prospective primary care cohort of people with chronic kidney disease stage 3. BMJ Open 2017; 7(8): e016528. doi: 10.1136/bmjopen-2017-016528

366. Seiler-Mussler S, Limbach AS, Emrich IE et al. Association of Nonoxidized Parathyroid Hormone with Cardiovascular and Kidney Disease Outcomes in Chronic Kidney Disease. Clin J Am Soc Nephrol 2018; 13(4): 569 - 576. doi: 10.2215/CJN.06620617

367. Tentori F, Wang M, Bieber BA et al. Recent changes in therapeutic approaches and association with outcomes among patients with secondary hyperparathyroidism on chronic hemodialysis: the DOPPS study. Clin J Am Soc Nephrol 2015; 10(1): 98 - 109. doi: 10.2215/CJN.12941213

368. Tentori F, Zepel L, Fuller DS et al. The DOPPS Practice Monitor for US Dialysis Care: PTH Levels and Management of Mineral and Bone Disorder in US Hemodialysis Patients. Am J Kidney Dis 2015; 66(3): 536 - 9. doi: 10.1053/j.ajkd.2015.07.011

369. Kandula P, Dobre M, Schold JD et al. Vitamin D supplementation in chronic kidney disease: a systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011; 6(1): 50 - 62. doi: 10.2215/CJN.03940510

370. Theodoratou E, Tzoulaki I, Zgaga L, Ioannidis JP. Vitamin D and multiple health outcomes: umbrella review of systematic reviews and meta-analyses of observational studies and randomised trials. BMJ 2014; 348: g2035. doi: 10.1136/bmj.g2035

371. Xu C, Li YC, Zhao SM, Li ZX. Evaluation of responses to vitamin D3 (cholecalciferol) in patients on dialysis: a systematic review and meta-analysis. J Investig Med 2016; 64(5): 1050 - 9. doi: 10.1136/jim-2015-000032

372. Bover J, Gunnarsson J, Csomor P et al. Impact of nutritional vitamin D supplementation on parathyroid hormone and 25-hydroxyvitamin D levels in non-dialysis chronic kidney disease: a meta-analysis. Clin Kidney J 2021; 14(10): 2177 - 2186. doi: 10.1093/ckj/sfab035

373. Tripkovic L, Lambert H, Hart K et al. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr 2012; 95(6): 1357 - 64. doi: 10.3945/ajcn.111.031070

374. Cardoso MP, Pereira LAL. Native vitamin D in pre-dialysis chronic kidney disease. Nefrologia 2019; 39(1): 18 - 28. doi: 10.1016/j.nefro.2018.07.004

375. Ennis JL, Worcester EM, Coe FL, Sprague SM. Current recommended 25-hydroxyvitamin D targets for chronic kidney disease management may be too low. J Nephrol 2016; 29(1): 63 - 70. doi: 10.1007/s40620-015-0186-0

376. Hu X, Shang J, Yuan W et al. Effects of paricalcitol on cardiovascular outcomes and renal function in patients with chronic kidney disease: A meta-analysis. Herz 2018; 43(6): 518 - 528. doi: 10.1007/s00059-017-4605-y

377. Liu Y, Liu LY, Jia Y et al. Efficacy and safety of paricalcitol in patients undergoing hemodialysis: a meta-analysis. Drug Des Devel Ther 2019; 13: 999 - 1009. doi: 10.2147/DDDT.S176257

378. Zhang T, Ju H, Chen H, Wen W. Comparison of Paricalcitol and Calcitriol in Dialysis Patients With Secondary Hyperparathyroidism: A Meta-Analysis of Randomized Controlled Studies. Ther Apher Dial 2019; 23(1): 73 - 79. doi: 10.1111/1744-9987.12760

379. Cai P, Tang X, Qin W et al. Comparison between paricalcitol and active non-selective vitamin D receptor activator for secondary hyperparathyroidism in chronic kidney disease: a systematic review and meta-analysis of randomized controlled trials. Int Urol Nephrol 2016; 48(4): 571 - 84. doi: 10.1007/s11255-015-1195-6

380. Xie Y, Su P, Sun Y et al. Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials. BMC Nephrol 2017; 18(1): 272. doi: 10.1186/s12882-017-0691-6

381. Ye H, Ye P, Zhang Z et al. A Bayesian network analysis on comparative efficacy of treatment strategies for dialysis patients with secondary hyperparathyroidism. Exp Ther Med 2019; 17(1): 531 - 540. doi: 10.3892/etm.2018.6906

382. Zheng Z, Shi H, Jia J et al. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol 2013; 14: 199. doi: 10.1186/1471-2369-14-199

383. He L, Li Y, Jin J et al. Comparative efficacy of sodium thiosulfate, bisphosphonates, and cinacalcet for the treatment of vascular calcification in patients with haemodialysis: a systematic review and network meta-analysis. BMC Nephrol 2024; 25(1): 26. doi: 10.1186/s12882-024-03460-x

384. Chandran M, Bilezikian JP, Lau J et al. The efficacy and safety of cinacalcet in primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials and cohort studies. Rev Endocr Metab Disord 2022; 23(3): 485 - 501. doi: 10.1007/s11154-021-09694-6

385. Lozano-Ortega G, Waser N, Bensink ME et al. Effects of calcimimetics on long-term outcomes in dialysis patients: literature review and Bayesian meta-analysis. J Comp Eff Res 2018; 7(7): 693 - 707. doi: 10.2217/cer-2018-0015

386. Zu Y, Lu X, Song J et al. Cinacalcet Treatment Significantly Improves All-Cause and Cardiovascular Survival in Dialysis Patients: Results from a Meta-Analysis. Kidney Blood Press Res 2019; 44(6): 1327 - 1338. doi: 10.1159/000504139

387. Sekercioglu N, Busse JW, Sekercioglu MF et al. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis. Ren Fail 2016; 38(6): 857 - 74. doi: 10.3109/0886022X.2016.1172468

388. Ballinger AE, Palmer SC, Nistor I et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2014; 2014(12): CD006254

389. Jin L, Zhou J, Shao F, Yang F. Long-term effects on PTH and mineral metabolism of 1.25 versus 1.75 mmol/L dialysate calcium in peritoneal dialysis patients: a meta-analysis. BMC Nephrol 2019; 20(1): 213. doi: 10.1186/s12882-019-1388-9

390. Ok E, Asci G, Bayraktaroglu S et al. Reduction of Dialysate Calcium Level Reduces Progression of Coronary Artery Calcification and Improves Low Bone Turnover in Patients on Hemodialysis. J Am Soc Nephrol 2016; 27(8): 2475 - 86. doi: 10.1681/ASN.2015030268

391. Spasovski G, Gelev S, Masin-Spasovska J et al. Improvement of bone and mineral parameters related to adynamic bone disease by diminishing dialysate calcium. Bone 2007; 41(4): 698 - 703. doi: 10.1016/j.bone.2007.06.014

392. Yoshikawa M, Takase O, Tsujimura T et al. Long-term effects of low calcium dialysates on the serum calcium levels during maintenance hemodialysis treatments: A systematic review and meta-analysis. Sci Rep 2018; 8(1): 5310. doi: 10.1038/s41598-018-23658-y

393. Palmer SC, Nistor I, Craig JC et al. Cinacalcet in patients with chronic kidney disease: a cumulative meta-analysis of randomized controlled trials. PLoS Med 2013; 10(4): e1001436. doi: 10.1371/journal.pmed.1001436

394. Ballinger AE, Palmer SC, Nistor I et al. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev 2014; (12): CD006254. doi: 10.1002/14651858.CD006254.pub2

395. Palmer SC, Mavridis D, Johnson DW et al. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis. Am J Kidney Dis 2020; 76(3): 321 - 330. doi: 10.1053/j.ajkd.2020.02.439

396. Xu J, Yang Y, Ma L et al. Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials. Int Urol Nephrol 2019; 51(11): 2027 - 2036. doi: 10.1007/s11255-019-02271-6

397. Block GA, Bushinsky DA, Cunningham J et al. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA 2017; 317(2): 146 - 155. doi: 10.1001/jama.2016.19456

398. Chen L, Wang K, Yu S et al. Long-term mortality after parathyroidectomy among chronic kidney disease patients with secondary hyperparathyroidism: a systematic review and meta-analysis. Ren Fail 2016; 38(7): 1050 - 8. doi: 10.1080/0886022X.2016.1184924

399. Apetrii M, Goldsmith D, Nistor I et al. Impact of surgical parathyroidectomy on chronic kidney disease-mineral and bone disorder (CKD-MBD) - A systematic review and meta-analysis. PLoS One 2017; 12(11): e0187025. doi: 10.1371/journal.pone.0187025

400. Schneider R, Kolios G, Koch BM et al. An economic comparison of surgical and medical therapy in patients with secondary hyperparathyroidism--the German perspective. Surgery 2010; 148(6): 1091 - 9. doi: 10.1016/j.surg.2010.09.009

401. Narayan R, Perkins RM, Berbano EP et al. Parathyroidectomy versus cinacalcet hydrochloride-based medical therapy in the management of hyperparathyroidism in ESRD: a cost utility analysis. Am J Kidney Dis 2007; 49(6): 801 - 13. doi: 10.1053/j.ajkd.2007.03.009

402. Hou J, Shan H, Zhang Y et al. Network meta-analysis of surgical treatment for secondary hyperparathyroidism. Am J Otolaryngol 2020; 41(2): 102370. doi: 10.1016/j.amjoto.2019.102370

403. Liu ME, Qiu NC, Zha SL et al. To assess the effects of parathyroidectomy (TPTX versus TPTX+AT) for Secondary Hyperparathyroidism in chronic renal failure: A Systematic Review and Meta-Analysis. Int J Surg 2017; 44: 353 - 362. doi: 10.1016/j.ijsu.2017.06.029

404. Yuan Q, Liao Y, Zhou R et al. Subtotal parathyroidectomy versus total parathyroidectomy with autotransplantation for secondary hyperparathyroidism: an updated systematic review and meta-analysis. Langenbecks Arch Surg 2019; 404(6): 669 - 679. doi: 10.1007/s00423-019-01809-7

405. Клинические рекомендации. Анемия при хронической болезни почек. 2020. https://cr.minzdrav.gov.ru/recomend/623_4

406. Korevaar JC, Feith GW, Dekker FW et al. Effect of starting with hemodialysis compared with peritoneal dialysis in patients new on dialysis treatment: a randomized controlled trial. Kidney Int 2003; 64(6): 2222 - 8. doi: 10.1046/j.1523-1755.2003.00321.x

407. Devoe DJ, Wong B, James MT et al. Patient Education and Peritoneal Dialysis Modality Selection: A Systematic Review and Meta-analysis. Am J Kidney Dis 2016; 68(3): 422 - 33. doi: 10.1053/j.ajkd.2016.02.053

408. Garofalo C, Borrelli S, De Stefano T et al. Incremental dialysis in ESRD: systematic review and meta-analysis. J Nephrol 2019; 32(5): 823 - 836. doi: 10.1007/s40620-018-00577-9

409. Liem YS, Bosch JL, Hunink MG. Preference-based quality of life of patients on renal replacement therapy: a systematic review and meta-analysis. Value Health 2008; 11(4): 733 - 41. doi: 10.1111/j.1524-4733.2007.00308.x

410. Han SS, Park JY, Kang S et al. Dialysis Modality and Mortality in the Elderly: A Meta-Analysis. Clin J Am Soc Nephrol 2015; 10(6): 983 - 93. doi: 10.2215/CJN.05160514

411. Lozier MR, Sanchez AM, Lee JJ et al. Comparison of Cardiovascular Outcomes by Dialysis Modality: A Systematic Review and Meta-Analysis. Perit Dial Int 2019; 39(4): 306 - 314. doi: 10.3747/pdi.2018.00227

412. Boonpheng B, Thongprayoon C, Cheungpasitporn W. The comparison of risk of stroke in patients with peritoneal dialysis and hemodialysis: A systematic review and meta-analysis. J Evid Based Med 2018; 11(3): 158 - 168. doi: 10.1111/jebm.12315

413. Zazzeroni L, Pasquinelli G, Nanni E et al. Comparison of Quality of Life in Patients Undergoing Hemodialysis and Peritoneal Dialysis: a Systematic Review and Meta-Analysis. Kidney Blood Press Res 2017; 42(4): 717 - 727. doi: 10.1159/000484115

414. Ravani P, Palmer SC, Oliver MJ et al. Associations between hemodialysis access type and clinical outcomes: a systematic review. J Am Soc Nephrol 2013; 24(3): 465 - 73. doi: 10.1681/ASN.2012070643

415. Almasri J, Alsawas M, Mainou M et al. Outcomes of vascular access for hemodialysis: A systematic review and meta-analysis. J Vasc Surg 2016; 64(1): 236 - 43. doi: 10.1016/j.jvs.2016.01.053

416. Smart NA, Dieberg G, Ladhani M, Titus T. Early referral to specialist nephrology services for preventing the progression to end-stage kidney disease. Cochrane Database Syst Rev 2014; (6): CD007333. doi: 10.1002/14651858.CD007333.pub2

417. Добронравов В.А., Карунная А.В. Прогностическое значение условий оптимального начала диализа (метаанализ обсервационных исследований). Нефрология 2021; 25(4): 42 - 47. doi: 10.36485/1561-6274-2021-25-4-42-47

418. Chan MR, Dall AT, Fletcher KE et al. Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med 2007; 120(12): 1063 - 1070. doi: 10.1016/j.amjmed.2007.04.024

419. Yin Y, Cao Y, Yuan L. Outcome and Safety of Unplanned-Start Peritoneal Dialysis according to Break-In Periods: A Systematic Review and Meta-Analysis. Blood Purif 2021; 50(2): 161 - 173. doi: 10.1159/000510550

420. Htay H, Johnson DW, Craig JC et al. Urgent-start peritoneal dialysis versus conventional-start peritoneal dialysis for people with chronic kidney disease. Cochrane Database Syst Rev 2020; 12: CD012913. doi: 10.1002/14651858.CD012913.pub2

421. Metcalfe W, Khan IH, Prescott GJ et al. Can we improve early mortality in patients receiving renal replacement therapy? Kidney Int 2000; 57(6): 2539 - 2545. doi: 10.1046/j.1523-1755.2000.00113.x

422. Descamps C, Labeeuw M, Trolliet P et al. Confounding factors for early death in incident end-stage renal disease patients: Role of emergency dialysis start. Hemodial Int 2011; 15(1): 23 - 9. doi: 10.1111/j.1542-4758.2010.00513.x

423. Michel A, Pladys A, Bayat S et al. Deleterious effects of dialysis emergency start, insights from the French REIN registry. BMC Nephrol 2018; 19(1): 233. doi: 10.1186/s12882-018-1036-9

424. Liu FX, Ghaffari A, Dhatt H et al. Economic evaluation of urgent-start peritoneal dialysis versus urgent-start hemodialysis in the United States. Medicine (Baltimore) 2014; 93(28): e293. doi: 10.1097/MD.0000000000000293

425. Mendelssohn DC, Malmberg C, Hamandi B. An integrated review of "unplanned" dialysis initiation: reframing the terminology to "suboptimal" initiation. BMC Nephrol 2009; 10: 22. doi: 10.1186/1471-2369-10-22

426. Cooper BA, Branley P, Bulfone L et al. A randomized, controlled trial of early versus late initiation of dialysis. N Engl J Med 2010; 363(7): 609 - 19. doi: 10.1056/NEJMoa1000552

427. Susantitaphong P, Altamimi S, Ashkar M et al. GFR at initiation of dialysis and mortality in CKD: a meta-analysis. Am J Kidney Dis 2012; 59(6): 829 - 40. doi: 10.1053/j.ajkd.2012.01.015

428. Pan Y, Xu XD, Guo LL et al. Association of early versus late initiation of dialysis with mortality: systematic review and meta-analysis. Nephron Clin Pract 2012; 120(3): c121 - 31. doi: 10.1159/000337572

429. Zhao Y, Pei X, Zhao W. Timing of Dialysis Initiation and Mortality Risk in Chronic Kidney Disease: A Meta-Analysis. Ther Apher Dial 2018; 22(6): 600 - 608. doi: 10.1111/1744-9987.12721

430. Xieyi G, Xiaohong T, Xiaofang W, Zi L. Urgent-start peritoneal dialysis in chronic kidney disease patients: A systematic review and meta-analysis compared with planned peritoneal dialysis and with urgent-start hemodialysis. Perit Dial Int 2020; 896860820918710. doi: 10.1177/0896860820918710

431. Bhandari B, Komanduri S. Dialysis Disequilibrium Syndrome. [Updated 2021 Jun 7]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2021. Available from: https://www.ncbi.nlm.nih.gov/books/NBK559018/

432. Mistry K. Dialysis disequilibrium syndrome prevention and management. Int J Nephrol Renovasc Dis 2019; 12: 69 - 77. doi: 10.2147/IJNRD.S165925

433. Mah DY, Yia HJ, Cheong WS. Dialysis disequilibrium syndrome: a preventable fatal acute complication. Med J Malaysia 2016; 71: 91 - 2

434. Brown RS, Patibandla BK, Goldfarb-Rumyantzev AS. The Survival Benefit of "Fistula First, Catheter Last" in Hemodialysis Is Primarily Due to Patient Factors. J Am Soc Nephrol 2017; 28(2): 645 - 652. doi: 10.1681/ASN.2016010019

435. Murad MH, Elamin MB, Sidawy AN et al. Autogenous versus prosthetic vascular access for hemodialysis: a systematic review and meta-analysis. J Vasc Surg 2008; 48(5 Suppl): 34S - 47S. doi: 10.1016/j.jvs.2008.08.044

436. Georgiadis GS, Charalampidis DG, Argyriou C et al. The Necessity for Routine Pre-operative Ultrasound Mapping Before Arteriovenous Fistula Creation: A Meta-analysis. Eur J Vasc Endovasc Surg 2015; 49(5): 600 - 5. doi: 10.1016/j.ejvs.2015.01.012

437. Aragoncillo Sauco I, Ligero Ramos JM, Vega A et al. Vascular access clinic results before and after implementing a multidisciplinary approach adding routine Doppler ultrasound. Nefrologia 018; 38(6): 616 - 621. doi: 10.1016/j.nefro.2018.04.003

438. Kensinger C, Brownie E, Bream P Jr, Moore D. Multidisciplinary team approach to end-stage dialysis access patients. J Surg Res 2015; 199(1): 259 - 65. doi: 10.1016/j.jss.2015.04.088

439. Bylsma LC, Gage SM, Reichert H et al. Arteriovenous Fistulae for Haemodialysis: A Systematic Review and Meta-analysis of Efficacy and Safety Outcomes. Eur J Vasc Endovasc Surg 2017; 54(4): 513 - 522. doi: 10.1016/j.ejvs.2017.06.024

440. Harms JC, Rangarajan S, Young CJ et al. Outcomes of arteriovenous fistulas and grafts with or without intervention before successful use. J Vasc Surg 2016; 64(1): 155 - 62. doi: 10.1016/j.jvs.2016.02.033

441. Lok CE, Sontrop JM, Tomlinson G et al. Cumulative patency of contemporary fistulas versus grafts (2000 - 2010). Clin J Am Soc Nephrol 2013; 8(5): 810 - 8. doi: 10.2215/CJN.00730112

442. Maya ID, O'Neal JC, Young CJ et al. Outcomes of brachiocephalic fistulas, transposed brachiobasilic fistulas, and upper arm grafts. Clin J Am Soc Nephrol 2009; 4(1): 86 - 92. doi: 10.2215/CJN.02910608

443. Astor BC, Eustace JA, Powe NR et al. Timing of nephrologist referral and arteriovenous access use: the CHOICE study. Am J Kidney Dis 2001; 38: 494 - 501. doi: 10.1053/ajkd.2001.2683

444. Begin V, Ethier J, Dumont M, Leblanc M. Prospective evaluation of the intra-access flow of recently created native arteriovenous fistulae. Am J Kidney Dis 2002; 40(6): 1277 - 82. doi: 10.1053/ajkd.2002.36898

445. Basile C, Lomonte C, Vernaglione L et al. The relationship between the flow of arteriovenous fistula and cardiac output in haemodialysis patients. Nephrol Dial Transplant 2008; 23(1): 282 - 7. doi: 10.1093/ndt/gfm549

446. Al-Ghonaim M, Manns BJ, Hirsch DJ et al. Relation between access blood flow and mortality in chronic hemodialysis patients. Clin J Am Soc Nephrol 2008; 3(2): 387 - 91. doi: 10.2215/CJN.03000707

447. Saleh MA, El Kilany WM, Keddis VW, El Said TW. Effect of high flow arteriovenous fistula on cardiac function in hemodialysis patients. Egypt Heart J 2018; 70(4): 337 - 341. doi: 10.1016/j.ehj.2018.10.007

448. Kordzadeh A, Chung J, Panayiotopoulos YP. Cephalic vein and radial artery diameter in formation of radiocephalic arteriovenous fistula: a systematic review. J Vasc Access 2015; 16: 506 - 11. doi: 10.5301/jva.5000413

449. Aitken E, Jackson A, Kearns R et al. Effect of regional versus local anesthesia on outcome after arteriovenous fistula creation: a randomized controlled trial. Lancet 2016; 388: 1067 - 1074. doi: 10.1016/S0140-6736(16)30948-5

450. Ismail A, Abushouk AI, Bekhet AH et al. Regional versus local anesthesia for arteriovenous fistula creation in end-stage renal disease: a systematic review and meta-analysis. J Vasc Access 2017; 18: 177 - 184. doi: 10.5301/jva.5000683

451. Gao C, Weng C, He C et al. Comparison of regional and local anesthesia for arteriovenous fistula creation in end-stage renal disease: a systematic review and meta-analysis. BMC Anesthesiol 2020; 20(1): 219. doi: 10.1186/s12871-020-01136-1

452. Palmer SC, Di Micco L, Razavian M et al. Antiplatelet therapy to prevent hemodialysis vascular access failure: systematic review and meta-analysis. Am J Kidney Dis 2013; 61(1): 112 - 22. doi: 10.1053/j.ajkd.2012.08.031

453. Dember LM, Beck GJ, Allon M et al. Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial. JAMA 2008; 299(18): 2164 - 71. doi: 10.1001/jama.299.18.2164

454. Tanner NC, Da Silva A. Medical adjuvant treatment to increase patency of arteriovenous fistulae and grafts. Cochrane Database Syst Rev 2015; 2015(7): CD002786. doi: 10.1002/14651858.CD002786.pub3

455. Smith GE, Souroullos P, Cayton T et al. A systematic review and meta-analysis of systemic intraoperative anticoagulation during arteriovenous access formation for dialysis. J Vasc Access 2016; 17: 1 - 5. doi: 10.5301/jva.5000484

456. Rayner HC, Pisoni RL, Gillespie BW et al. Creation, cannulation and survival of arteriovenous fistulae: data from the Dialysis Outcomes and Practice Patterns Study. Kidney Int 2003; 63(1): 323 - 30. doi: 10.1046/j.1523-1755.2003.00724.x

457. Saran R, Dykstra DM, Pisoni RL et al. Timing of first cannulation and vascular access failure in haemodialysis: an analysis of practice patterns at dialysis facilities in the DOPPS. Nephrol Dial Transplant 2004; 19(9): 2334 - 40. doi: 10.1093/ndt/gfh363

458. Ravani P, Brunori G, Mandolfo S et al. Cardiovascular comorbidity and late referral impact arteriovenous fistula survival: a prospective multicenter study. J Am Soc Nephrol 2004; 15(1): 204 - 9. doi: 10.1097/01.asn.0000103870.31606.90

459. Wilmink T, Hollingworth L, Stevenson T, Powers S. Is early cannulation of an arteriovenous fistula associated with early failure of the fistula? J Vasc Access 2017; 18(Suppl. 1): 92 - 97. doi: 10.5301/jva.5000674

460. Allon M, Imrey PB, Cheung AK et al. Relationships Between Clinical Processes and Arteriovenous Fistula Cannulation and Maturation: A Multicenter Prospective Cohort Study. Am J Kidney Dis 2018; 71(5): 677 - 689. doi: 10.1053/j.ajkd.2017.10.027

461. Wilmink T, Powers S, Hollingworth L, Stevenson T. Effect of first cannulation time and dialysis machine blood flows on survival of arteriovenous fistulas. Nephrol Dial Transplant 2018; 33(5): 841 - 846. doi: 10.1093/ndt/gfx278

462. Ferring M, Henderson J, Wilmink T. Accuracy of early postoperative clinical and ultrasound examination of arteriovenous fistulae to predict dialysis use. J Vasc Access 2014; 15(4): 291 - 7. doi: 10.5301/jva.5000210

463. Stewart AH, Eyers PS, Earnshaw JJ. Prevention of infection in peripheral arterial reconstruction: a systematic review and meta-analysis. J Vasc Surg 2007; 46(1): 148 - 55. doi: 10.1016/j.jvs.2007.02.065

464. Feldman L, Shani M, Mursi J et al. Effect of timing of the first cannulation on survival of arteriovenous hemodialysis grafts. Ther Apher Dial 2013; 17(1): 60 - 4. doi: 10.1111/j.1744-9987.2012.01134.x

465. Schild AF, Schuman ES, Noicely K et al. Early cannulation prosthetic graft (Flixene^TM) for arteriovenous access. J Vasc Access 2011; 12(3): 248 - 52. doi: 10.5301/jva.2011.6351

466. Hakaim AG, Scott TE. Durability of early prosthetic dialysis graft cannulation: results of a prospective, nonrandomized clinical trial. J Vasc Surg 1997; 25(6): 1002 - 5. doi: 10.1016/s0741-5214(97)70123-x

467. Glickman MH, Burgess J, Cull D et al. Prospective multicenter study with a 1-year analysis of a new vascular graft used for early cannulation in patients undergoing hemodialysis. J Vasc Surg 2015; 62(2): 434 - 41. doi: 10.1016/j.jvs.2015.03.020

468. National Kidney Foundation. KDOQI Clinical Practice Guideline for Vascular Access: 2019 Update. Am J Kidney Dis 2020; 75(4 Suppl 2): S1 - S164. doi: 10.1053/j.ajkd.2019.12.001

469. Diskin CJ, Stokes TJ, Panus LW et al. The importance of timing of surgery for hemodialysis vascular access thrombectomy. Nephron 1997; 75: 233 - 237. doi: 10.1159/000189538

470. Sadaghianloo N, Jean-Baptiste E, Gaid H et al. Early surgical thrombectomy improves salvage of thrombosed vascular accesses. J Vasc Surg 2014; 59: 1377 - 1384. e1 - 2. doi: 10.1016/j.jvs.2013.11.092

471. Green LD, Lee DS, Kucey DS. A metaanalysis comparing surgical thrombectomy, mechanical thrombectomy, and pharmacomechanical thrombolysis for thrombosed dialysis grafts. J Vasc Surg 2002; 36(5): 939 - 45. doi: 10.1067/mva.2002.127524

472. Chan N, Wee I, Soong TK et al. A systematic review and meta-analysis of surgical versus endovascular thrombectomy of thrombosed arteriovenous grafts in hemodialysis patients. J Vasc Surg 2019; 69(6): 1976 - 1988. e7. doi: 10.1016/j.jvs.2018.10.102

473. Kuhan G, Antoniou GA, Nikam M et al. A meta-analysis of randomized trials comparing surgery versus endovascular therapy for thrombosed arteriovenous fistulas and grafts in hemodialysis. Cardiovasc Intervent Radiol 2013; 36(3): 699 - 705. doi: 10.1007/s00270-013-0564-8

474. Doelman C, Duijm LE, Liem YS et al. Stenosis detection in failing hemodialysis access fistulas and grafts: comparison of color Doppler ultrasonography, contrast-enhanced magnetic resonance angiography, and digital subtraction angiography. J Vasc Surg 2005; 42(4): 739 - 46. doi: 10.1016/j.jvs.2005.06.006

475. Tessitore N, Bedogna V, Gammaro L et al. Diagnostic accuracy of ultrasound dilution access blood flow measurement in detecting stenosis and predicting thrombosis in native forearm arteriovenous fistulae for hemodialysis. Am J Kidney Dis 2003; 42(2): 331 - 41. doi: 10.1016/s0272-6386(03)00659-0

476. Tonelli M, James M, Wiebe N et al. Ultrasound monitoring to detect access stenosis in hemodialysis patients: a systematic review. Am J Kidney Dis 2008; 51(4): 630 - 40. doi: 10.1053/j.ajkd.2007.11.025

477. Schwarz C, Mitterbauer C, Boczula M et al. Flow monitoring: performance characteristics of ultrasound dilution versus color Doppler ultrasound compared with fistulography. Am J Kidney Dis 2003; 42(3): 539 - 45. doi: 10.1016/s0272-6386(03)00786-8

478. Rooijens PP, Serafino GP, Vroegindeweij D et al. Multi-slice computed tomographic angiography for stenosis detection in forearm hemodialysis arteriovenous fistulas. J Vasc Access 2008; 9(4): 278 - 84

479. Karadeli E, Tarhan NC, Ulu EM et al. Evaluation of failing hemodialysis fistulas with multidetector CT angiography: comparison of different 3D planes. Eur J Radiol 2009; 69(1): 184 - 92. doi: 10.1016/j.ejrad.2007.09.014

480. Dimopoulou A, Raland H, B, Magnusson A. MDCT angiography with 3D image reconstructions in the evaluation of failing arteriovenous fistulas and grafts in hemodialysis patients. Acta Radiol 2011; 52(9): 935 - 42. doi: 10.1258/ar.2011.110255

481. Wasinrat J, Siriapisith T, Thamtorawat S, Tongdee T. 64-slice MDCT angiography of upper extremity in assessment of native hemodialysis access. Vasc Endovascular Surg 2011; 45(1): 69 - 77. doi: 10.1177/1538574410379922

482. Yan Wee IJ, Yap HY, Hsien Ts'ung LT et al. A systematic review and meta-analysis of drug-coated balloon versus conventional balloon angioplasty for dialysis access stenosis. J Vasc Surg 2019; 70(3): 970 - 979.e3. doi: 10.1016/j.jvs.2019.01.082

483. Hu H, Wu Z, Zhao J et al. Stent graft placement versus angioplasty for hemodialysis access failure: a meta-analysis. J Surg Res 2018; 226: 82 - 88. doi: 10.1016/j.jss.2018.01.030

484. Agarwal SK, Nadkarni GN, Yacoub R et al. Comparison of Cutting Balloon Angioplasty and Percutaneous Balloon Angioplasty of Arteriovenous Fistula Stenosis: A Meta-Analysis and Systematic Review of Randomized Clinical Trials. J Interv Cardiol 2015; 28(3): 288 - 95. doi: 10.1111/joic.12202

485. Kundu S. Review of central venous disease in hemodialysis patients. J Vasc Intervent Radiol 2010; 21: 963 - 8. doi: 10.1016/j.jvir.2010.01.044

486. Ozyer U, Harman A, Yildirim E et al. Long-term results of angioplasty and stent placement for treatment of central venous obstruction in 126 hemodialysis patients: a 10-year single-center experience. AJR Am J Roentgenol 2009; 193(6): 1672 - 9. doi: 10.2214/AJR.09.2654

487. Quaretti P, Galli F, Moramarco LP et al. Stent Grafts Provided Superior Primary Patency for Central Venous Stenosis Treatment in Comparison with Angioplasty and Bare Metal Stent: A Retrospective Single Center Study on 70 Hemodialysis Patients. Vasc Endovascular Surg 2016; 50(4): 221 - 30. doi: 10.1177/1538574416639149

488. Kumbar L, Yee J. Current Concepts in Hemodialysis Vascular Access Infections. Adv Chronic Kidney Dis 2019; 26(1): 16 - 22. doi: 10.1053/j.ackd.2018.10.005

489. Padberg Jr FT, Calligaro KD, Sidawy AN. Complications of arteriovenous hemodialysis access: recognition and management. J Vasc Surg 2008; 48: 55S-80S. doi: 10.1016/j.jvs.2008.08.067

490. Ryan SV, Calligaro KD, Dougherty MJ. Management of hemodialysis access infections. Semin Vasc Surg 2004; 17: 40 - 4. doi: 10.1053/j.semvascsurg.2003.11.004

491. Benrashid E, Youngwirth LM, Mareeba L, Lawsoneffrey JH. Operative and perioperative management of infected arteriovenous grafts. J Vasc Access 2017; 18(1): 13 - 21. doi: 10.5301/jva.5000613

492. Schutte WP, Helmer SD, Salazar L, Smith JL. Surgical treatment of infected prosthetic dialysis arteriovenous grafts: total versus partial graft excision. Comparative Study. Am J Surg 2007; 193: 385 - 8

493. Furukawa H. Surgical management of vascular access related aneurysms to salvage dialysis access: case report and a systematic review of the literature. J Vasc Access 2015; 16(2): 120 - 5. doi: 10.5301/jva.5000319

494. Georgiadis GS, Lazarides MK, Panagoutsos SA et al. Surgical revision of complicated false and true vascular access-related aneurysms. Multicenter Study. J Vasc Surg 2008; 47: 1284 - 91. doi: 10.1016/j.jvs.2008.01.051

495. Shemesh D, Goldin I, Zaghal I et al. Stent graft treatment for hemodialysis access aneurysms. J Vasc Surg 2011; 54: 1088 - 94 doi: 10.1016/j.jvs.2011.03.252

496. Pandolfe LR, Malamis AP, Pierce K, Borge MA. Treatment of hemodialysis graft pseudoaneurysms with stent grafts: institutional experience and review of the literature. Semin Intervent Radiol 2009; 26: 89 - 95

497. Spergel LM, Ravani P, Roy-Chaudhury P et al. Surgical salvage of the autogenous arteriovenous fistula (AVF). J Nephrol 2007; 20: 388 - 98

498. Thomson P, Stirling C, Traynor J et al. A prospective observational study of catheter-related bacteraemia and thrombosis in a haemodialysis cohort: univariate and multivariate analyses of risk association. Nephrol Dial Transplant 2010; 25(5): 1596 - 604. doi: 10.1093/ndt/gfp667

499. Shingarev R, Barker-Finkel J, Allon M. Natural history of tunneled dialysis catheters placed for hemodialysis initiation. J Vasc Interv Radiol 2013; 24(9): 1289 - 94. doi: 10.1016/j.jvir.2013.05.034

500. Oliver MJ, Callery SM, Thorpe KE et al. Risk of bacteremia from temporary hemodialysis catheters by site of insertion and duration of use: a prospective study. Kidney Int 2000; 58(6): 2543 - 5. doi: 10.1046/j.1523-1755.2000.00439.x

501. Hryszko T, Brzosko S, Mazerska M et al. Risk factors of nontunneled noncuffed hemodialysis catheter malfunction. A prospective study. Nephron Clin Pract 2004; 96(2): c43 - 7. doi: 10.1159/000076398

502. Engstrom BI, Horvath JJ, Stewart JK et al. Tunneled internal jugular hemodialysis catheters: impact of laterality and tip position on catheter dysfunction and infection rates. J Vasc Interv Radiol 2013; 24(9): 1295 - 302. doi: 10.1016/j.jvir.2013.05.035

503. Oguzkurt L, Tercan F, Torun D, et al. Impact of short-term hemodialysis catheters on the central veins: a catheter venographic study. Eur J Radiol 2004; 52: 293 - 299. doi: 10.1016/j.ejrad.2003.12.004

504. Cimochowski GE, Worley E, Rutherford WE et al. Superiority of the internal jugular over the subclavian access for temporary dialysis. Nephron 1990; 54(2): 154 - 61. doi: 10.1159/000185837

505. Oliver MJ, Edwards LJ, Treleaven DJ et al. Randomized study of temporary hemodialysis catheters. Int J Artif Organs 2002; 25(1): 40 - 4. doi: 10.1177/039139880202500107

506. Salik E, Daftary A, Tal MG. Three-dimensional anatomy of the left central veins: implications for dialysis catheter placement. J Vasc Interv Radiol 2007; 18: 361 - 364. doi: 10.1016/ j. jvir.2006.12.721

507. Schillinger F, Schillinger D, Montagnac R, Milcent T. Post catheterisation vein stenosis in haemodialysis: comparative angiographic study of 50 subclavian and 50 internal jugular accesses. Nephrol Dial Transplant 1991; 6(10): 722 - 4. doi: 10.1093/ndt/6.10.722

508. Schwab SJ, Quarles LD, Middleton JP et al. Hemodialysis-associated subclavian vein stenosis. Kidney Int 1988; 33(6): 1156 - 9. doi: 10.1038/ki.1988.124

509. Naumovic RT, Jovanovic DB, Djukanovic LJ. Temporary vascular catheters for hemodialysis: a 3-year prospective study. Int J Artif Organs 2004; 27(10): 848 - 54. doi: 10.1177/039139880402701006

510. Falk A. Use of the femoral vein as insertion site for tunneled hemodialysis catheters. J Vasc Interv Radiol 2007; 18(2): 217 - 25. doi: 10.1016/j.jvir.2006.12.001

511. Randolph AG, Cook DJ, Gonzales CA, Pribble CG. Ultrasound guidance for placement of central venous catheters: a meta-analysis of the literature. Crit Care Med 1996; 24(12): 2053 - 8. doi: 10.1097/00003246-199612000-00020

512. Hind D, Calvert N, McWilliams R et al. Ultrasonic locating devices for central venous cannulation: meta-analysis. BMJ 2003; 327(7411): 361. doi: 10.1136/bmj.327.7411.361

513. Rabindranath KS, Kumar E, Shail R, Vaux E. Use of real-time ultrasound guidance for the placement of hemodialysis catheters: a systematic review and meta-analysis of randomized controlled trials. Am J Kidney Dis 2011; 58(6): 964 - 70. doi: 10.1053/j.ajkd.2011.07.025

514. Bansal R, Agarwal S, Tiwari SC, Dash SC. A prospective randomized study to compare ultrasound-guided with non-ultrasound guided double lumen internal jugular catheter insertion as a temporary hemodialysis access. Ren Fail 2005; 27: 561 - 564. doi: 10.1080/08860220500199084

515. Allon M, Brouwer-Maier DJ, Abreo K et al. Recommended Clinical Trial End Points for Dialysis Catheters. Clin J Am Soc Nephrol 2018; 13(3): 495 - 500. doi: 10.2215/CJN.12011116

516. Yevzlin AS, Song GU, Sanchez RJ, Becker YT. Fluoroscopically guided vs modified traditional placement of tunneled hemodialysis catheters: clinical outcomes and cost analysis. J Vasc Access 2007; 8: 245 - 251

517. Wong SS, Kwaan HC, Ing TS. Venous air embolism related to the use of central catheters revisited: with emphasis on dialysis catheters. Clin Kidney J 2017; 10: 797 - 803. doi: 10.1093/ckj/sfx064

518. Beathard GA, Litchfield T. Physician Operators Forum of RMS Lifeline, Inc. Effectiveness and safety of dialysis vascular access procedures performed by interventional nephrologists. Kidney Int 2004; 66: 1622 - 1632. doi: 10.1111/j.1523-1755.2004.00928.x

519. Abood GJ, Davis KA, Esposito TJ et al. Comparison of routine chest radiograph versus clinician judgment to determine adequate central line placement in critically ill patients. J Trauma 2007; 63: 50 - 56. doi: 10.1097/TA.0b013e31806bf1a3

520. Chalkiadis GA, Goucke CR. Depth of central venous catheter insertion in adults: an audit and assessment of a technique to improve tip position. Anaesthesiol Intensive Care 1998; 26: 61 - 66. doi: 10.1177/0310057X9802600109

521. Aboelela SW, Stone PW, Larson EL. Effectiveness of bundled behavioural interventions to control healthcare-associated infections: a systematic review of the literature. J Hosp Infect 2007; 66(2): 101 - 108. doi: 10.1016/j.jhin.2006.10.019

522. Blot K, Bergs J, Vogelaers D et al. Prevention of central line-associated bloodstream infections through quality improvement interventions: a systematic review and meta-analysis. Clin Infect Dis 2014; 59: 96 - 105. doi: 10.1093/cid/ciu239

523. Rosenblum A, Wang W, Ball LK et al. Hemodialysis catheter care strategies: a cluster-randomized quality improvement initiative. Am J Kidney Dis 2014; 63(2): 259 - 67. doi: 10.1053/j.ajkd.2013.08.019

524. Silva TN, de Marchi D, Mendes ML et al. Approach to prophylactic measures for central venous catheter-related infections in hemodialysis: a critical review. Hemodial Int 2014; 18: 15 - 23. doi: 10.1111/hdi.12071

525. American Society of Anesthesiologists Task Force on Central Venous Access. Practice guidelines for central venous access: a report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology 2012; 116(3): 539 - 73. doi: 10.1097/ALN.0b013e31823c9569

526. СанПиН 2.1.3.2630-10 "Санитарно-эпидемиологические требования к организациям, осуществляющим медицинскую деятельность" (с изменениями на 10 июня 2016 года)

527. Приказ Росстандарта от 31 марта 2015 года N 199-ст утвержден ГОСТ Р 52623.3-2015 "Технологии выполнения простых медицинских услуг. Манипуляции сестринского ухода"

528. Клинические рекомендации. Профилактика катетер-ассоциированных инфекций кровотока и уход за центральным венозным катетером (ЦВК), 2017 год. https://zdrav36.ru/files/fkr-2017-profilaktika-kateter-associirovannyh-infekcij-krovotoka.pdf

529. Raad II, Hohn DC, Gilbreath BJ et al. Prevention of central venous catheter-related infections by using maximal sterile barrier precautions during insertion. Infect Control Hosp Epidemiol 1994; 15: 231 - 23

530. Safdar N, Abad C. Educational interventions for prevention of healthcare-associated infection: a systematic review. Crit Care Med 2008; 36(3): 933 - 940. doi: 10.1097/CCM.0B013E318165FAF3

531. Ma IW, Brindle ME, Ronksley PE et al. Use of simulation-based education to improve outcomes of central venous catheterization: a systematic review and meta-analysis. Acad Med 2011; 86(9): 1137 - 1147. doi: 10.1097/ACM.0b013e318226a204

532. Chaiyakunapruk N, Veenstra DL, Lipsky BA et al. Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med 2002; 136: 792 - 801. doi: 10.7326/0003-4819-136-11-200206040-00007

533. Mimoz O, Lucet JC, Kerforne T et al. Skin antisepsis with chlorhexidine-alcohol versus povidone iodine-alcohol, with and without skin scrubbing, for prevention of intravascularcatheter-related infection (CLEAN): an open-label, multicentre, randomised, controlled, two-by-two factorial trial. Lancet 2015; 386: 2069 - 2077. doi: 10.1016/S0140-6736(15)00244-5

534. Gilles D, O'Riordan L, Carr D et al. Gauze and tape and transparent polyurethane dressings for central venous catheters. Meta-analysis Cochrane Database Systematic Review 2003; 4: CD003827. doi: 10.1002/14651858.CD003827

535. Ho KM, Litton E. Use of chlorhexidine-impregnated dressing to prevent vascular and epidural catheter colonization and infection: a meta-analysis. J Antimicrob Chemother 2006; 58: 281 - 7. doi: 10.1093/jac/dkl234

536. Hoffmann KK, Weber DJ, Samsa GP, Rutala WA. Transparent polyurethane film as an intravenous catheter dressing. A meta-analysis of the infection risks. JAMA 1992; 267(15): 2072 - 2076

537. Le Corre I, Delorme M, Cournoyer S. A prospective, randomized trial comparing a transparent dressing and a dry gauze on the exit site of long term central venous catheters of hemodialysis patients. The Journal of Vascular Access 2003; 4: 56 - 61

538. Betjes MGH. Prevention of catheter-related bloodstream infection in patients on hemodialysis. Review. Nat Rev Nephrol 2011; 7: 257 - 265. doi: 10.1038/nrneph.2011.28

539. James MT, Conley J, Tonelli M et al. Meta-analysis: antibiotics for prophylaxis against hemodialysis catheter-related infections. Ann Intern Med 2008; 148: 596 - 605. doi: 10.7326/0003-4819-148-8-200804150-00004

540. Johnson DW, MacGinley R, Kay TD et al. A randomized controlled trial of topical exit site mupirocin application in patients with tunnelled, cuffed haemodialysis catheters. Nephrol Dial Transplant 2002; 17(10): 1802 - 1807. doi: 10.1093/ndt/17.10.1802

541. Tacconelli E, Carmeli Y, Aizer A et al. Mupirocin prophylaxis to prevent Staphylococcus aureus infection in patients undergoing dialysis: a meta-analysis. Clin Infect Dis 2003; 37: 1629 - 1638

542. Rabindranath KS, Bansal T, Adams J et al. Systematic review of antimicrobials for the prevention of haemodialysis catheter-related infections. Nephrology Dialysis Transplantation 2009; 24: 3763 - 74. doi: 10.1093/ndt/gfp327

543. Boelaert JR, De Smedt RA, De Baere YA et al. The influence of calcium mupirocin nasal ointment on the incidence of Staphylococcus aureus infections in haemodialysis patients. Randomized clinical trial. Nephrol Dial Transplant 1989; 4: 278 - 81. doi: 10.1093/oxfordjournals.ndt.a091872

544. Sesso R, Barbosa D, Leme IL et al. Staphylococcus aureus prophylaxis in hemodialysis patients using central venous catheters: effect of mupirocin ointment. Randomized clinical trial. J Am Soc Nephrol 1998; 9: 1085 - 92. doi: 10.1681/ASN.V961085

545. Chapla K, Oza-Gajera BP, Yevzlin AS et al. Hemodialysis catheter locking solutions and the prevention of catheter dysfunction: a meta-analysis. J Vasc Access 2015; 16(2): 107 - 12. doi: 10.5301/jva.5000312

546. Bosma JW, Siegert CE, Peerbooms PG et al. Reduction of biofilm formation with trisodium citrate in haemodialysis catheters: a randomized controlled trial. Nephrol Dial Transplant 2010; 25: 1213 - 1217. doi: 10.1093/ndt/gfp651

547. Han X, Yang X, Huang B et al. Low-dose versus high-dose heparin locks for hemodialysis catheters: a systematic review and meta-analysis. Clin Nephrol 2016; 86(7): 1 - 8. doi: 10.5414/CN108701

548. Zhao Y, Li Z, Zhang L et al. Citrate versus heparin lock for hemodialysis catheters: a systematic review and meta-analysis of randomized controlled trials. Am J Kidney Dis 2014; 63: 479 - 490. doi: 10.1053/j.ajkd.2013.08.016

549. Jinrui J, Wang Ch, Zhao H et al. Anticoagulant therapies versus heparin for the prevention of hemodialysis catheter-related complications: systematic review and meta-analysis of prospective randomized controlled trials. Int J Clin Exp Med 2015; 8(8): 11985 - 11995

550. Pollo V, D, Bucuvic EM et al. Alteplase vs. urokinase for occluded hemodialysis catheter: A randomized trial. Hemodial Int 2016; 20(3): 378 - 84. doi: 10.1111/hdi.12391

551. Al-Ali F, Hamdy AF, Hamad A et al. Safety and efficacy of taurolidine/urokinase versus taurolidine/heparin as a tunneled catheter lock solution in hemodialysis patients: a prospective, randomized, controlled study. Nephrol Dial Transplant 2018; 33(4): 619 - 626. doi: 10.1093/ndt/gfx187

552. Winnicki W, Herkner H, Lorenz M et al. Taurolidine-based catheter lock regimen significantly reduces overall costs, infection, and dysfunction rates of tunneled hemodialysis catheters. Kidney Int 2018; 93(3): 753 - 760. doi: 10.1016/j.kint.2017.06.026

553. Zwiech R, Adelt M, Chrul S. A Taurolidine-Citrate-Heparin Lock Solution Effectively Eradicates Pathogens from the Catheter Biofilm in Hemodialysis Patients. Am J Ther 2016; 23(2): e363 - 8. doi: 10.1097/MJT.0b013e31828d4610

554. Solomon LR, Cheesbrough JS, Bhargava R et al. Observational study of need for thrombolytic therapy and incidence of bacteremia using taurolidine-citrate-heparin, taurolidine-citrate and heparin catheter locks in patients treated with hemodialysis. Semin Dial 2012; 25(2): 233 - 8. doi: 10.1111/j.1525-139X.2011.00951

555. Bonkain F, Van Hulle F, Janssens P et al. Urokinase-containing locking solution in the prevention of dialysis catheter dysfunction: a double blind randomized controlled trial. J Vasc Access 2017; 18(5): 436 - 442. doi: 10.5301/jva.5000737

556. Liu H, Liu H, Deng J et al. Preventing catheter-related bacteremia with taurolidine-citrate catheter locks: a systematic review and meta-analysis. Blood Purif 2014; 37(3): 179 - 87. doi: 10.1159/000360271

557. Allon M. Dialysis catheter-related bacteremia: treatment and prophylaxis. Am J Kidney Dis 2004; 44(5): 779 - 91

558. Kumbar L, Yee J. Current Concepts in Hemodialysis Vascular Access Infections. Adv Chronic Kidney Dis 2019; 26(1): 16 - 22. doi: 10.1053/j.ackd.2018.10.005

559. Mickley V. Central venous catheters: many questions, few answers. Nephrol Dial Transplant 2002; 17: 1368 - 1373. DOI: 10.1093/ndt/17.8.1368

560. Weijmer MC, Vervloet MG, ter Wee PM. Compared to tunnelled cuffed haemodialysis catheters, temporary untunnelled catheters are associated with more complications already within 2 weeks of use. Nephrol Dial Transplant 2004; 19(3): 670 - 7. doi: 10.1093/ndt/gfg581

561. NEW D'cruz RT, Leong SW, Syn N et al. Endovascular treatment of cephalic arch stenosis in brachiocephalic arteriovenous fistulas: A systematic review and meta-analysis. J Vasc Access 2019; 20(4): 345 - 355. doi: 10.1177/1129729818814466

562. NEW Wu TY, Wu CK, Chen YY, Lin CH. Comparison of Percutaneous Transluminal Angioplasty with Stenting for Treatment of Central Venous Stenosis or Occlusion in Hemodialysis Patients: A Systematic Review and Meta-analysis. Cardiovasc Intervent Radiol 2020; 43(4): 525 - 540. doi: 10.1007/s00270-019-02383-7

563. Dammers R, de Haan MW, Planken NR et al. Central vein obstruction in hemodialysis patients: results of radiological and surgical intervention. Eur J Vasc Endovasc Surg 2003; 26(3): 317 - 21. doi: 10.1053/ejvs.2002.1943

564. Sprouse LR 2nd, Lesar CJ, Meier GH 3rd et al. Percutaneous treatment of symptomatic central venous stenosis. J Vasc Surg 2004; 39(3): 578 - 82. doi: 10.1016/j.jvs.2003.09.034

565. Bakken AM, Protack CD, Saad WE et al. Long-term outcomes of primary angioplasty and primary stenting of central venous stenosis in hemodialysis patients. J Vasc Surg 2007; 45(4): 776 - 83. doi: 10.1016/j.jvs.2006.12.046

566. Ozyer U, Harman A, Yildirim E et al. Long-term results of angioplasty and stent placement for treatment of central venous obstruction in 126 hemodialysis patients: a 10-year single-center experience. AJR Am J Roentgenol 2009; 193(6): 1672 - 9. doi: 10.2214/AJR.09.2654

567. Maya ID, Saddekni S, Allon M. Treatment of refractory central vein stenosis in hemodialysis patients with stents. Semin Dial 2007; 20(1): 78 - 82. doi: 10.1111/j.1525-139X.2007.00246.x

568. Kim YC, Won JY, Choi SY et al. Percutaneous treatment of central venous stenosis in hemodialysis patients: long-term outcomes. Cardiovasc Intervent Radiol 2009; 32(2): 271 - 8. doi: 10.1007/s00270-009-9511-0

569. Anaya-Ayala JE, Smolock CJ, Colvard BD et al. Efficacy of covered stent placement for central venous occlusive disease in hemodialysis patients. J Vasc Surg 2011; 54(3): 754 - 9. doi: 10.1016/j.jvs.2011.03.260

570. Kundu S, Modabber M, You JM et al. Use of PTFE stent grafts for hemodialysis-related central venous occlusions: intermediate-term results. Cardiovasc Intervent Radiol 2011; 34(5): 949 - 57. doi: 10.1007/s00270-010-0019-4

571. Quaretti P, Galli F, Moramarco LP et al. Stent Grafts Provided Superior Primary Patency for Central Venous Stenosis Treatment in Comparison with Angioplasty and Bare Metal Stent: A Retrospective Single Center Study on 70 Hemodialysis Patients. Vasc Endovascular Surg 2016; 50(4): 221 - 30. doi: 10.1177/1538574416639149

572. Ronald J, Davis B, Guevara CJ et al. Treatment of central venous in-stent restenosis with repeat stent deployment in hemodialysis patients. J Vasc Access 2017; 18(3): 214 - 219. doi: 10.5301/jva.5000705

573. Swaminathan S, Mor V, Mehrotra R, Trivedi AN. Initial Session Duration and Mortality Among Incident Hemodialysis Patients. Am J Kidney Dis 2017; 70(1): 69 - 75. doi: 10.1053/j.ajkd.2016.11.017

574. Flythe JE, Curhan GC, Brunelli SM. Shorter length dialysis sessions are associated with increased mortality, independent of body weight. Kidney Int 2013; 83(1): 104 - 13. doi: 10.1038/ki.2012.346

575. Ko GJ, Obi Y, Soohoo M et al. No Survival Benefit in Octogenarians and Nonagenarians with Extended Hemodialysis Treatment Time. Am J Nephrol 2018; 48(5): 389 - 398. doi: 10.1159/000494336

576. Mathew A, McLeggon JA, Mehta N et al. Mortality and Hospitalizations in Intensive Dialysis: A Systematic Review and Meta-Analysis. Can J Kidney Health Dis 2018; 5: 2054358117749531. doi: 10.1177/2054358117749531

577. Jansz TT, Noordzij M, Kramer A et al. Survival of patients treated with extended-hours haemodialysis in Europe: an analysis of the ERA-EDTA Registry. Nephrol Dial Transplant 2020; 35(3): 488 - 495. doi: 10.1093/ndt/gfz208

578. Greene T, Daugirdas J, Depner T et al. Association of achieved dialysis dose with mortality in the hemodialysis study: an example of "dose-targeting bias". J Am Soc Nephrol 2005; 16(11): 3371 - 80. doi: 10.1681/ASN.2005030321

579. Sridharan S, Vilar E, Davenport A et al. Indexing dialysis dose for gender, body size and physical activity: Impact on survival. PLoS One 2018; 13(9): e0203075. doi: 10.1371/journal.pone.0203075

580. Miller JE, Kovesdy CP, Nissenson AR et al. Association of hemodialysis treatment time and dose with mortality and the role of race and sex. Am J Kidney Dis 2010; 55(1): 100 - 12. doi: 10.1053/j.ajkd.2009.08.007

581. Eknoyan G, Beck GJ, Cheung AK et al. Effect of dialysis dose and membrane flux in maintenance hemodialysis. N Engl J Med 2002; 347(25): 2010 - 9. doi: 10.1056/NEJMoa021583

582. European Best Practice Guidelines Expert Group on Hemodialysis, European Renal Association. Section II. Haemodialysis adequacy. Nephrol Dial Transplant 2002; 17 Suppl 7: 16 - 31

583. Ahrenholz P, Taborsky P, Bohling M et al. Determination of dialysis dose: a clinical comparison of methods. Blood Purif 2011; 32(4): 271 - 7. doi: 10.1159/000330340

584. Rabindranath KS, Strippoli GF, Roderick P et al. Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic review. Am J Kidney Dis 2005; 45(3): 437 - 47. doi: 10.1053/j.ajkd.2004.11.008

585. Nistor I, Palmer SC, Craig JC et al. Haemodiafiltration, haemofiltration and haemodialysis for end-stage kidney disease. Cochrane Database Syst Rev 2015; (5): CD006258. doi: 10.1002/14651858.CD006258.pub2

586. Liu Y, Zou W, Wu J et al. Comparison between incremental and thrice-weekly haemodialysis: Systematic review and meta-analysis. Nephrology (Carlton) 2019; 24(4): 438 - 444. doi: 10.1111/nep.13252

587. M, Teruel-Briones JL, Gomis A et al. Recovery of renal function in patients receiving haemodialysis treatment. Nefrologia 2012; 32(2): 166 - 71. doi: 10.3265/Nefrologia.pre2011.Dec.11194

588. Tattersall J. Residual renal function in incremental dialysis. Clin Kidney J 2018; 11(6): 853 - 856. doi: 10.1093/ckj/sfy082

589. Vartia A. Residual renal function in incremental haemodialysis. Clin Kidney J 2018; 11(6): 857 - 863. doi: 10.1093/ckj/sfy036

590. Daugirdas JT. Residual renal function in incremental haemodialysis. Clin Kidney J 2018; 11(6): 857 - 863. doi: 10.1093/ckj/sfy036

591. Obi Y, Rhee CM, Mathew AT et al. Residual Kidney Function Decline and Mortality in Incident Hemodialysis Patients. J Am Soc Nephrol 2016; 27(12): 3758 - 3768. doi: 10.1681/ASN.2015101142

592. Paniagua R, Amato D, Vonesh E et al. Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol 2002; 13(5): 1307 - 20

593. Termorshuizen F, Korevaar JC, Dekker FW et al. The relative importance of residual renal function compared with peritoneal clearance for patient survival and quality of life: an analysis of the Netherlands Cooperative Study on the Adequacy of Dialysis (NECOSAD)-2. Am J Kidney Dis 2003; 41(6): 1293 - 302

594. CANUSA Peritoneal Dialysis Study Group. Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol 2001; 12(10): 2158 - 62

595. Lu W, Ren C, Han X et al. The protective effect of different dialysis types on residual renal function in patients with maintenance hemodialysis: A systematic review and meta-analysis. Medicine (Baltimore) 2018; 97(37): e12325. doi: 10.1097/MD.0000000000012325

596. Wang M, Obi Y, Streja E et al. Impact of residual kidney function on hemodialysis adequacy and patient survival. Nephrol Dial Transplant 2018; 33(10): 1823 - 1831. doi: 10.1093/ndt/gfy060

597. Daugirdas JT, Depner TA, Greene T et al. Standard Kt/Vurea: a method of calculation that includes effects of fluid removal and residual kidney clearance. Kidney Int 2010; 77(7): 637 - 44. doi: 10.1038/ki.2009.525

598. Casino FG, Basile C. A user-friendly tool for incremental haemodialysis prescription. Nephrol Dial Transplant 2018; 33(6): 1046 - 1053. doi: 10.1093/ndt/gfx343

599. Palmer SC, Rabindranath KS, Craig JC et al. High-flux versus low-flux membranes for end-stage kidney disease. Cochrane Database Syst Rev 2012; 2012(9): CD005016. doi: 10.1002/14651858.CD005016.pub2

600. Zhao F, Wang Z, Liu L, Wang S. The influence of mortality rate from membrane flux for end-stage renal disease: A meta-analysis. Nephrol Ther 2017; 13(1): 9 - 13. doi: 10.1016/j.nephro.2016.07.445

601. Li X, Xu H, Xiao XC et al. Prognostic effect of high-flux hemodialysis in patients with chronic kidney disease. Braz J Med Biol Res 2016; 49(1): e4708. doi: 10.1590/1414-431X20154708

602. Peters SA, Bots ML, Canaud B et al. Haemodiafiltration and mortality in end-stage kidney disease patients: a pooled individual participant data analysis from four randomized controlled trials. Nephrol Dial Transplant 2016; 31(6): 978 - 84. doi: 10.1093/ndt/gfv349

603. Masakane I, Kikuchi K, Kawanishi H. Evidence for the Clinical Advantages of Predilution On-Line Hemodiafiltration. Contrib Nephrol 2017; 189: 17 - 23. doi: 10.1159/000450635

604. Wang AY, Ninomiya T, Al-Kahwa A et al. Effect of hemodiafiltration or hemofiltration compared with hemodialysis on mortality and cardiovascular disease in chronic kidney failure: a systematic review and meta-analysis of randomized trials. Am J Kidney Dis 2014; 63(6): 968 - 78. doi: 10.1053/j.ajkd.2014.01.435

605. Liu S, Liu H, Wang Z et al. Effect of changing treatment to high-flux hemodialysis (HFHD) on mortality in patients with long-term low flux hemodialysis (LFHD): a propensity score matched cohort study. BMC Nephrol 2020; 21(1): 485. doi: 10.1186/s12882-020-02145-5

606. Nistor I, Palmer SC, Craig JC et al. Convective versus diffusive dialysis therapies for chronic kidney failure: an updated systematic review of randomized controlled trials. Am J Kidney Dis 2014; 63(6): 954 - 67. doi: 10.1053/j.ajkd.2013.12.004

607. Mostovaya IM, Blankestijn PJ, Bots ML et al. Clinical evidence on hemodiafiltration: a systematic review and a meta-analysis. Semin Dial 2014; 27(2): 119 - 27. doi: 10.1111/sdi.12200

608. Maduell F, Moreso F, Pons M et al. High-efficiency postdilution online hemodiafiltration reduces all-cause mortality in hemodialysis patients. J Am Soc Nephrol 2013; 24: 487 - 497. doi: 10.1681/ASN.2012080875

609. Grooteman MP, van den Dorpel MA, Bots ML et al. Effect of online hemodiafiltration on all-cause mortality and cardiovascular outcomes. J Am Soc Nephrol 2012; 23: 1087 - 1096. doi: 10.1681/ASN.2011121140

610. Ok E, Asci G, Toz H et al. Mortality and cardiovascular events in online haemodiafiltration (OL-HDF) compared with high-flux dialysis: results from the Turkish OL-HDF Study. Nephrol Dial Transplant 2013; 28: 192 - 202. doi: 10.1093/ndt/gfs407

611. Davenport A, Peters SA, Bots ML et al. Higher convection volume exchange with online hemodiafiltration is associated with survival advantage for dialysis patients: the effect of adjustment for body size. Kidney Int 2016; 89: 193 - 199. doi: 10.1038/ki.2015.264

612. Tsuchida K, Minakuchi J. Clinical benefits of predilution on-line hemodiafiltration. Blood Purif 2013; 35(Suppl 1): 18 - 22. doi: 10.1159/000346221

613. Macleod AM, Campbell M, Cody JD et al. Cellulose, modified cellulose and synthetic membranes in the haemodialysis of patients with end-stage renal disease. Cochrane Database Syst Rev 2005; (3): CD003234. doi: 10.1002/14651858.CD003234.pub2

614. Ashby D, Borman N, Burton J et al. Renal Association Clinical Practice Guideline on Haemodialysis. BMC Nephrol 2019; 20(1): 379. doi: 10.1186/s12882-019-1527-3

615. Tielemans C, Madhoun P, Lenaers M et al. Anaphylactoid reactions during hemodialysis on AN69 membranes in patients receiving ACE inhibitors. Kidney Int 1990; 38: 982 - 984

616. Martin-Navarroa J, Esterasb R, Castillo E et al. Reactions to synthetic membranes dialyzers: is there an increase in incidence? Kidney Blood Press Res 2019; 44(5): 907 - 914

617. Wilson B, Harwood L. Reaching Consensus on Outcomes for Successful Cannulation of an Arteriovenous Fistula: Patient and Healthcare Provider Perspectives. Nephrol Nurs J 2018; 45: 327 - 336

618. Lazrak HH, , Elftouh N et al. Safety of low-molecular-weight heparin compared to unfractionated heparin in hemodialysis: a systematic review and meta-analysis. BMC Nephrol 2017; 18(1): 187. doi: 10.1186/s12882-017-0596-4

619. Lim W, Cook DJ, Crowther MA. Safety and efficacy of low molecular weight heparins for haemodialysis in patients with end-stage renal failure: a metaanalysis of randomised trials. J Am Soc Nephrol 2004; 15: 3192 - 206

620. Palamaner Subash Shantha G, Kumar AA, Sethi M et al. Efficacy and safety of low molecular weight heparin compared to unfractionated heparin for chronic outpatient hemodialysis in end stage renal disease: systematic review and meta-analysis. Peer J 2015; 3: e835

621. Davenport A. Optimization of heparin anticoagulation for hemodialysis. Hemodial Int 2011; 15 Suppl 1: S43 - 8. doi: 10.1111/j.1542-4758.2011.00601.x

622. Шило В.Ю. Низкомолекулярные гепарины в гемодиализе: многолетний опыт применения далтепарина. Клиницист. 2008: 2; 55 - 57

623. Строков А.Г., Поз Я.Л. Антикоагуляция при заместительной почечной терапии: классические подходы и новые возможности. Вестник трансплантологии и искусственных органов. 2010; 4: 80 - 85

624. Fischer KG. Essentials of anticoagulation in hemodialysis. Hemodial Int 2007; 11(2): 178 - 89. doi: 10.1111/j.1542-4758.2007.00166.x

625. Susantitaphong P, Riella C, Jaber BL. Effect of ultrapure dialysate on markers of inflammation, oxidative stress, nutrition and anemia parameters: a meta-analysis. Nephrol Dial Transplant 2013; 28(2): 438 - 46. doi: 10.1093/ndt/gfs514

626. Flythe JE, Kshirsagar AV, Falk RJ, Brunelli SM. Associations of Posthemodialysis Weights above and below Target Weight with All-Cause and Cardiovascular Mortality. Clin J Am Soc Nephrol 2015; 10(5): 808 - 16. doi: 10.2215/CJN.10201014

627. Sands JJ, Usvyat LA, Sullivan T et al. Intradialytic hypotension: frequency, sources of variation and correlation with clinical outcome. Hemodial Int 2014; 18(2): 415 - 22. doi: 10.1111/hdi.12138

628. Kraemer M, Rode C, Wizemann V. Detection limit of methods to assess fluid status changes in dialysis patients. Kidney Int 2006; 69: 1609 - 1620. doi: 10.1038/sj.ki.5000286

629. Piccoli A. Identification of operational clues to dry weight prescription in hemodialysis using bioimpedance vector analysis. The Italian Hemodialysis-Bioelectrical Impedance Analysis (HD-BIA) Study Group. Kidney Int 1998; 53: 1036 - 1043

630. Tao WW, Tao XM, Wang Y, Bi SH. Psycho-social and educational interventions for enhancing adherence to dialysis in adults with end-stage renal disease: A meta-analysis. J Clin Nurs 2020; 29(15-16): 2834 - 2848. doi: 10.1111/jocn.15301

631. Murali KM, Mullan J, Roodenrys S et al. Strategies to improve dietary, fluid, dialysis or medication adherence in patients with end stage kidney disease on dialysis: A systematic review and meta-analysis of randomized intervention trials. PLoS One 2019; 14(1): e0211479. doi: 10.1371/journal.pone.0211479

632. Huang M, Lv A, Wang J et al. Exercise Training and Outcomes in Hemodialysis Patients: Systematic Review and Meta-Analysis. Am J Nephrol 2019; 50(4): 240 - 254. doi: 10.1159/000502447

633. Scapini KB, Bohlke M, Moraes OA et al. Combined training is the most effective training modality to improve aerobic capacity and blood pressure control in people requiring haemodialysis for end-stage renal disease: systematic review and network meta-analysis. J Physiother 2019; 65(1): 4 - 15. doi: 10.1016/j.jphys.2018.11.008

634. Salhab N, Karavetian M, Kooman J et al. Effects of intradialytic aerobic exercise on hemodialysis patients: a systematic review and meta-analysis. J Nephrol 2019; 32(4): 549 - 566. doi: 10.1007/s40620-018-00565-z

635. Dobsak P, Homolka P, Svojanovsky J et al. Intra-dialytic electrostimulation of leg extensors may improve exercise tolerance and quality of life in hemodialyzed patients. Artif Organs 2012; 36(1): 71 - 8. doi: 10.1111/j.1525-1594.2011.01302.x

636. EBPG Expert Group on Peritoneal Dialysis. European best practice guidelines for peritoneal dialysis. 1 General guidelines. Nephrol Dial Transplant 2005; 20 Suppl 9: ix2. doi: 10.1093/ndt/gfi1115

637. Rabindranath KS, Adams J, Ali TZ et al. Continuous ambulatory peritoneal dialysis versus automated peritoneal dialysis for end-stage renal disease. Cochrane Database Syst Rev 2007(2): CD006515. doi: 10.1002/14651858.CD006515

638. Michels WM, van Dijk S, Verduijn M et al. Quality of life in automated and continuous ambulatory peritoneal dialysis. Perit Dial Int 2011; 31(2): 138 - 47. doi: 10.3747/pdi.2010.00063

639. Eloot S, Vanholder R, Dequidt C, Van Biesen W. Removal of Different Classes of Uremic Toxins in APD vs CAPD: A Randomized Cross-Over Study. Perit Dial Int 2015; 35(4): 436 - 42. doi: 10.3747/pdi.2013.00202

640. Johnson DW, Hawley CM, McDonald SP et al. Superior survival of high transporters treated with automated versus continuous ambulatory peritoneal dialysis. Nephrol Dial Transplant 2010; 25(6): 1973 - 9. doi: 10.1093/ndt/gfp780

641. Michels WM, Verduijn M, Grootendorst DC et al. Decline in residual renal function in automated compared with continuous ambulatory peritoneal dialysis. Clin J Am Soc Nephrol 2011; 6(3): 537 - 42. doi: 10.2215/CJN.00470110

642. M, C, Sans M et al. Compared decline of residual kidney function in patients treated with automated peritoneal dialysis and continuous ambulatory peritoneal dialysis: a multicenter study. Nephron Clin Pract 2014; 128(3-4): 352 - 60. doi: 10.1159/000368933

643. Ding L, Yang J, Li L, Yang Y. Effects of ACEIs and ARBs on the Residual Renal Function in Peritoneal Dialysis Patients: A Meta-Analysis of Randomized Controlled Trials. Biomed Res Int 2020; 2020: 6762029. doi: 10.1155/2020/6762029

644. Yoon HE, Kwon YJ, Shin SJ et al. Bioimpedance spectroscopy-guided fluid management in peritoneal dialysis patients with residual kidney function: A randomized controlled trial. Nephrology (Carlton) 2019; 24(12): 1279 - 1289. doi: 10.1111/nep.13571

645. Oh KH, Baek SH, Joo KW et al. Does Routine Bioimpedance-Guided Fluid Management Provide Additional Benefit to Non-Anuric Peritoneal Dialysis Patients? Results from COMPASS Clinical Trial. Perit Dial Int 2018; 38(2): 131 - 138. doi: 10.3747/pdi.2016.00241

646. Covic A, Ciumanghel AI, Siriopol D et al. Value of bioimpedance analysis estimated "dry weight" in maintenance dialysis patients: a systematic review and meta-analysis. Int Urol Nephrol 2017; 49(12): 2231 - 2245. doi: 10.1007/s11255-017-1698-4

647. Ng JK, Kwan BC, Chow KM et al. Asymptomatic fluid overload predicts survival and cardiovascular event in incident Chinese peritoneal dialysis patients. PLoS One 2018; 13(8): e0202203. doi: 10.1371/journal.pone.0202203

648. EBPG Expert Group on Peritoneal Dialysis. European best practice guidelines for peritoneal dialysis. 7 Adequacy of peritoneal dialysis. Nephrol Dial Transplant 2005; 20 Suppl 9: ix24 - ix27. doi: 10.1093/ndt/gfi1121

649. EAPOS Group. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003; 14(11): 2948 - 57. doi: 10.1097/01.asn.0000092146.67909.e2

650. Davies SJ, Brown EA, Reigel W et al. What is the link between poor ultrafiltration and increased mortality in anuric patients on automated peritoneal dialysis? Analysis of data from EAPOS. Perit Dial Int 2006; 26(4): 458 - 65

651. Woodrow G, Fan SL, Reid C et al. Renal Association Clinical Practice Guideline on peritoneal dialysis in adults and children. BMC Nephrol 2017; 18(1): 333. doi: 10.1186/s12882-017-0687-2

652. Brimble KS, Walker M, Margetts PJ et al. Meta-analysis: peritoneal membrane transport, mortality, and technique failure in peritoneal dialysis. J Am Soc Nephrol 2006; 17(9): 2591 - 8. doi: 10.1681/ASN.2006030194

653. Krediet RT, Struijk DG. Peritoneal dialysis membrane evaluation in clinical practice. Contrib Nephrol 2012; 178: 232 - 237. doi: 10.1159/000337884

654. La Milia V, Virga G, Amici G et al. Functional assessment of the peritoneal membrane. J Nephrol 2013; 26 Suppl 21: 120 - 39. doi: 10.5301/JN.2013.11637

655. Wen Y, Guo Q, Yang X et al. High glucose concentrations in peritoneal dialysate are associated with all-cause and cardiovascular disease mortality in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 2015; 35(1): 70 - 7. doi: 10.3747/pdi.2013.00083

656. Selby NM, Fialova J, Burton JO, McIntyre CW. The haemodynamic and metabolic effects of hypertonic-glucose and amino-acid-based peritoneal dialysis fluids. Nephrol Dial Transplant 2007; 22(3): 870 - 9. doi: 10.1093/ndt/gfl654

657. Netherlands Ultrafiltration Failure Study Group. Analysis of the prevalence and causes of ultrafiltration failure during long-term peritoneal dialysis: a cross-sectional study. Perit Dial Int 2004; 24(6): 562 - 70

658. A, Hylander B, Moritz A et al. Increase of intra-abdominal fat in patients treated with continuous ambulatory peritoneal dialysis. Perit Dial Int 1998; 18(2): 166 - 71

659. Selby NM, Fonseca S, Hulme L et al. Hypertonic glucose-based peritoneal dialysate is associated with higher blood pressure and adverse haemodynamics as compared with icodextrin. Nephrol Dial Transplant 2005; 20(9): 1848 - 53. doi: 10.1093/ndt/gfh946

660. Marshall J, Jennings P, Scott A et al. Glycemic control in diabetic CAPD patients assessed by continuous glucose monitoring system (CGMS). Kidney Int 2003; 64(4): 1480 - 6. doi: 10.1046/j.1523-1755.2003.00209.x

661. Htay H, Johnson DW, Wiggins KJ et al. Biocompatible dialysis fluids for peritoneal dialysis. Cochrane Database Syst Rev 2018; 10(10): CD007554. doi: 10.1002/14651858.CD007554.pub3

662. Qi H, Xu C, Yan H, Ma J. Comparison of icodextrin and glucose solutions for long dwell exchange in peritoneal dialysis: a meta-analysis of randomized controlled trials. Perit Dial Int 2011; 31(2): 179 - 88. doi: 10.3747/pdi.2009.00264

663. Goossen K, Becker M, Marshall MR et al. Icodextrin Versus Glucose Solutions for the Once-Daily Long Dwell in Peritoneal Dialysis: An Enriched Systematic Review and Meta-analysis of Randomized Controlled Trials. Am J Kidney Dis 2020; 75(6): 830 - 846. doi: 10.1053/j.ajkd.2019.10.004

664. Asola M, Virtanen K, K et al. Amino-acid-based peritoneal dialysis solution improves amino-acid transport into skeletal muscle. Kidney Int Suppl 2008; (108): S131 - 6. doi: 10.1038/sj.ki.5002614

665. Plum J, Erren C, Fieseler C et al. An amino acid-based peritoneal dialysis fluid buffered with bicarbonate versus glucose/bicarbonate and glucose/lactate solutions: an intraindividual randomized study. Perit Dial Int 1999; 19(5): 418 - 28

666. Jones M, Hagen T, Boyle CA et al. Treatment of malnutrition with 1.1% amino acid peritoneal dialysis solution: results of a multicenter outpatient study. Am J Kidney Dis 1998; 32(5): 761 - 9. doi: 10.1016/s0272-6386(98)70131-3

667. Li FK, Chan LY, Woo JC et al. A 3-year, prospective, randomized, controlled study on amino acid dialysate in patients on CAPD. Am J Kidney Dis 2003; 42(1): 173 - 83. doi: 10.1016/s0272-6386(03)00421-9

668. Tjiong HL, van den Berg JW, Wattimena JL et al. Dialysate as food: combined amino acid and glucose dialysate improves protein anabolism in renal failure patients on automated peritoneal dialysis. J Am Soc Nephrol 2005; 16(5): 1486 - 93. doi: 10.1681/ASN.2004050402

669. Wang J, Zhu N, Yuan W. Effect of neutral pH and low-glucose degradation product-containing peritoneal dialysis solution on residual renal function in peritoneal dialysis patients: a meta-analysis. Nephron 2015; 129(3): 155 - 63. doi: 10.1159/000368235

670. Yohanna S, Alkatheeri AM, Brimble SK et al. Effect of Neutral-pH, Low-Glucose Degradation Product Peritoneal Dialysis Solutions on Residual Renal Function, Urine Volume, and Ultrafiltration: A Systematic Review and Meta-Analysis. Clin J Am Soc Nephrol 2015; 10(8): 1380 - 8. doi: 10.2215/CJN.05410514

671. EBPG Expert Group on Peritoneal Dialysis. European best practice guidelines for peritoneal dialysis. 3 Peritoneal access. Nephrol Dial Transplant 2005; 20 Suppl 9: ix8 - ix12. doi: 10.1093/ndt/gfi1117

672. Gadallah MF, Pervez A, el-Shahawy MA et al. Peritoneoscopic versus surgical placement of peritoneal dialysis catheters: a prospective randomized study on outcome. Am J Kidney Dis 1999; 33(1): 118 - 22. doi: 10.1016/s0272-6386(99)70266-0

673. Qiao Q, Zhou L, Hu K et al. Laparoscopic versus traditional peritoneal dialysis catheter insertion: a meta analysis. Ren Fail 2016; 38(5): 838 - 48. doi: 10.3109/0886022X.2015.1077313

674. Lo WK, Ho YW, Li CS et al. Effect of Kt/V on survival and clinical outcome in CAPD patients in a randomized prospective study. Kidney Int 2003; 64(2): 649 - 56. doi: 10.1046/j.1523-1755.2003.00098.x

675. Canada-USA (CANUSA) Peritoneal Dialysis Study Group. Adequacy of dialysis and nutrition in continuous peritoneal dialysis: association with clinical outcomes. J Am Soc Nephrol 1996; 7(2): 198 - 207

676. Jansen MA, Termorshuizen F, Korevaar JC et al. Predictors of survival in anuric peritoneal dialysis patients. Kidney Int 2005; 68(3): 1199 - 205. doi: 10.1111/j.1523-1755.2005.00512.x

677. Szeto CC, Wong TY, Chow KM et al. Impact of dialysis adequacy on the mortality and morbidity of anuric Chinese patients receiving continuous ambulatory peritoneal dialysis. J Am Soc Nephrol 2001; 12(2): 355 - 60

678. Fried L, Hebah N, Finkelstein F, Piraino B. Association of Kt/V and creatinine clearance with outcomes in anuric peritoneal dialysis patients. Am J Kidney Dis 2008; 52: 1122 - 1130

679. Lo WK, Lui SL, Chan TM et al. Minimal and optimal peritoneal Kt/V targets: results of an anuric peritoneal dialysis patient's survival analysis. Kidney Int 2005; 67(5): 2032 - 8. doi: 10.1111/j.1523-1755.2005.00305.x

680. Kim DJ, Do JH, Huh WS et al. Dissociation between clearances of small and middle molecules in incremental peritoneal dialysis. Perit Dial Int 2001; 21: 462 - 466

681. Piraino B, Bernardini J, Brown E et al. ISPD position statement on reducing the risks of peritoneal dialysis-related infections. Perit Dial Int 2011; 31(6): 614 - 30. doi: 10.3747/pdi.2011.00057

682. Daly CD, Campbell MK, MacLeod AM et al. Do the Y-set and double-bag systems reduce the incidence of CAPD peritonitis? A systematic review of randomized controlled trials. Nephrol Dial Transplant 2001; 16(2): 341 - 7. doi: 10.1093/ndt/16.2.341

683. Daly C, Cody JD, Khan I et al. Double bag or Y-set versus standard transfer systems for continuous ambulatory peritoneal dialysis in end-stage kidney disease. Cochrane Database Syst Rev 2014; 2014(8): CD003078. doi: 10.1002/14651858.CD003078.pub2

684. Strippoli GF, Tong A, Johnson D et al. Catheter-related interventions to prevent peritonitis in peritoneal dialysis: A systematic review of randomized, controlled trials. J Am Soc Nephrol 2004; 15: 2735 - 2746

685. Bernardini J, Piraino B, Holley J et al. A randomized trial of Staphylococcus aureus prophylaxis in peritoneal dialysis patients: mupirocin calcium ointment 2% applied to the exit site versus cyclic oral rifampin. Am J Kidney Dis 1996; 27(5): 695 - 700. doi: 10.1016/s0272-6386(96)90105-5

686. Bernardini J, Bender F, Florio T et al. Randomized, double-blind trial of antibiotic exit site cream for prevention of exit site infection in peritoneal dialysis patients. J Am Soc Nephrol 2005; 16(2): 539 - 45. doi: 10.1681/ASN.2004090773

687. Campbell D, Mudge DW, Craig JC et al. Antimicrobial agents for preventing peritonitis in peritoneal dialysis patients. Cochrane Database Syst Rev 2017; 4(4): CD004679. doi: 10.1002/14651858.CD004679.pub3

688. Grothe C, Taminato M, Belasco A et al. Prophylactic treatment of chronic renal disease in patients undergoing peritoneal dialysis and colonized by Staphylococcus aureus: a systematic review and meta-analysis. BMC Nephrol 2016; 17(1): 115. doi: 10.1186/s12882-016-0329-0

689. Tsai CC, Yang PS, Liu CL et al. Comparison of topical mupirocin and gentamicin in the prevention of peritoneal dialysis-related infections: A systematic review and meta-analysis. Am J Surg 2018; 215(1): 179 - 185. doi: 10.1016/j.amjsurg.2017.03.005

690. Xu G, Tu W, Xu C. Mupirocin for preventing exit-site infection and peritonitis in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2010; 25(2): 587 - 92. doi: 10.1093/ndt/gfp411

691. Piraino B. Staphylococcus aureus infections in dialysis patients: focus on prevention. ASAIO J 2000; 46(6): S13 - 7. doi: 10.1097/00002480-200011000-00031

692. Li PK, Szeto CC, Piraino B et al. Peritoneal dialysis-related infections recommendations: 2010 update. Perit Dial Int 2010; 30(4): 393 - 423. doi: 10.3747/pdi.2010.00049

693. Li PK, Szeto CC, Piraino B et al. ISPD peritonitis recommendations: 2016 update on prevention and treatment. Perit Dial Int 2016; 36: 481 - 508

694. Barretti P, Doles JV, Pinotti DG, El Dib R. Efficacy of antibiotic therapy for peritoneal dialysis-associated peritonitis: a proportional meta-analysis. BMC Infect Dis 2014; 14: 445. doi: 10.1186/1471-2334-14-445

695. Ballinger AE, Palmer SC, Wiggins KJ et al. Treatment for peritoneal dialysis-associated peritonitis. Cochrane Database Syst Rev 2014; (4): CD005284. doi: 10.1002/14651858.CD005284.pub3

696. Chang TI, Kim HW, Park JT et al. Early catheter removal improves patient survival in peritoneal dialysis patients with fungal peritonitis: results of ninety-four episodes of fungal peritonitis at a single center. Perit Dial Int 2011; 31(1): 60 - 6. doi: 10.3747/pdi.2009.00057

697. Basturk T, Koc Y, Unsal A et al. Fungal peritonitis in peritoneal dialysis: a 10 year retrospective analysis in a single center. Eur Rev Med Pharmacol Sci 2012; 16(12): 1696 - 700

698. Wang AY, Yu AW, Li PK et al. Factors predicting outcome of fungal peritonitis in peritoneal dialysis: analysis of a 9-year experience of fungal peritonitis in a single center. Am J Kidney Dis 2000; 36(6): 1183 - 92. doi: 10.1053/ajkd.2000.19833

699. Miles R, Hawley CM, McDonald SP et al. Predictors and outcomes of fungal peritonitis in peritoneal dialysis patients. Kidney Int 2009; 76(6): 622 - 8. doi: 10.1038/ki.2009.202

700. Nadeau-Fredette AC, Bargman JM. Characteristics and outcomes of fungal peritonitis in a modern North American cohort. Perit Dial Int 2015; 35(1): 78 - 84. doi: 10.3747/pdi.2013.00179

701. ONTARGET Investigators. Population-Attributable Fractions of Modifiable Lifestyle Factors for CKD and Mortality in Individuals With Type 2 Diabetes: A Cohort Study. Am J Kidney Dis 2016; 68(1): 29 - 40. doi: 10.1053/j.ajkd.2015.12.019

702. Smart N, Steele M. Exercise training in haemodialysis patients: a systematic review and meta-analysis. Nephrology (Carlton) 2011; 16(7): 626 - 32. doi: 10.1111/j.1440-1797.2011.01471.x

703. Greenwood SA, Lindup H, Taylor K et al. Evaluation of a pragmatic exercise rehabilitation programme in chronic kidney disease. Nephrol Dial Transplant 2012; 27 Suppl 3: iii126 - 34. doi: 10.1093/ndt/gfs272

704. Tentori F, Elder SJ, Thumma J et al. Physical exercise among participants in the Dialysis Outcomes and Practice Patterns Study (DOPPS): correlates and associated outcomes. Nephrol Dial Transplant 2010; 25(9): 3050 - 62. doi: 10.1093/ndt/gfq138

705. Kurella Tamura M, Covinsky KE, Chertow GM et al. Functional status of elderly adults before and after initiation of dialysis. N Engl J Med 2009; 361(16): 1539 - 47. doi: 10.1056/NEJMoa0904655

706. McIntyre CW, Selby NM, Sigrist M et al. Patients receiving maintenance dialysis have more severe functionally significant skeletal muscle wasting than patients with dialysis-independent chronic kidney disease. Nephrol Dial Transplant 2006; 21(8): 2210 - 6. doi: 10.1093/ndt/gfl064

707. American College of Sports Medicine; American Heart Association. Physical activity and public health in older adults: recommendation from the American College of Sports Medicine and the American Heart Association. Circulation 2007; 116(9): 1094 - 105. doi: 10.1161/CIRCULATIONAHA.107.185650

708. Kosmadakis GC, Bevington A, Smith AC et al. Physical exercise in patients with severe kidney disease. Nephron Clin Pract 2010; 115(1): c7 - c16. doi: 10.1159/000286344

709. Intiso D, Di Rienzo F, Russo M et al. Rehabilitation strategy in the elderly. J Nephrol 2012; 25 Suppl 19: S90 - 5. doi: 10.5301/jn.5000138

710. Bowling CB, Muntner P, Sawyer P et al. Community mobility among older adults with reduced kidney function: a study of life-space. Am J Kidney Dis 2014; 63(3): 429 - 36. doi: 10.1053/j.ajkd.2013.07.022

711. Chin A Paw MJ, van Uffelen JG, Riphagen I, van Mechelen W. The functional effects of physical exercise training in frail older people: a systematic review. Sports Med 2008; 38(9): 781 - 93. doi: 10.2165/00007256-200838090-00006

712. Sugawara J, Miyachi M, Moreau KL et al. Age-related reductions in appendicular skeletal muscle mass: association with habitual aerobic exercise status. Clin Physiol Funct Imaging 2002; 22(3): 169 - 72. doi: 10.1046/j.1475-097x.2002.00413.x

713. Pavasini R, Guralnik J, Brown JC et al. Short Physical Performance Battery and all-cause mortality: systematic review and meta-analysis. BMC Med 2016; 14(1): 215. doi: 10.1186/s12916-016-0763-7

714. GBD 2013 Risk Factors Collaborators. Global, regional, and national comparative risk assessment of 79 behavioural, environmental and occupational, and metabolic risks or clusters of risks in 188 countries, 1990 - 2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015; 386(10010): 2287 - 2323. doi: 10.1016/S0140-6736(15)00128-2

715. Xu H, Suo J, Lian J. Cigarette smoking and risk of albuminuria in patients with type 2 diabetes: a systematic review and meta-analysis of observational studies. Int Urol Nephrol 2018; 50(5): 911 - 922. doi: 10.1007/s11255-018-1825-x

716. Liao D, Ma L, Liu J, Fu P. Cigarette smoking as a risk factor for diabetic nephropathy: A systematic review and meta-analysis of prospective cohort studies. PLoS One 2019; 14(2): e0210213. doi: 10.1371/journal.pone.0210213

717. Kar D, Gillies C, Nath M et al. Association of smoking and cardiometabolic parameters with albuminuria in people with type 2 diabetes mellitus: a systematic review and meta-analysis. Acta Diabetol 2019; 56(8): 839 - 850. doi: 10.1007/s00592-019-01293-x

718. Garofalo C, Borrelli S, Minutolo R et al. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int 2017; 91(5): 1224 - 1235. doi: 10.1016/j.kint.2016.12.013

719. Martens RJH, van der Berg JD, Stehouwer CDA et al. Amount and pattern of physical activity and sedentary behavior are associated with kidney function and kidney damage: The Maastricht Study. PLoS One 2018; 13(4): e0195306. doi: 10.1371/journal.pone.0195306

720. Parsons TJ, Sartini C, Ash S et al. Objectively measured physical activity and kidney function in older men; a cross-sectional population-based study. Age Ageing 2017; 46(6): 1010 - 1014. doi: 10.1093/ageing/afx091

721. Bach KE, Kelly JT, Palmer SC et al. Healthy Dietary Patterns and Incidence of CKD: A Meta-Analysis of Cohort Studies. Clin J Am Soc Nephrol 2019; 14(10): 1441 - 1449. doi: 10.2215/CJN.00530119

722. Mottl AK, Buse JB, Ismail-Beigi F et al. Long-Term Effects of Intensive Glycemic and Blood Pressure Control and Fenofibrate Use on Kidney Outcomes. Clin J Am Soc Nephrol 2018; 13(11): 1693 - 1702. doi: 10.2215/CJN.06200518

723. Ruospo M, Saglimbene VM, Palmer SC et al. Glucose targets for preventing diabetic kidney disease and its progression. Cochrane Database Syst Rev 2017; 6(6): CD010137. doi: 10.1002/14651858.CD010137.pub2

724. Persson F, Lindhardt M, Rossing P, Parving HH. Prevention of microalbuminuria using early intervention with renin-angiotensin system inhibitors in patients with type 2 diabetes: A systematic review. J Renin Angiotensin Aldosterone Syst 2016; 17(3): 1470320316652047. doi: 10.1177/1470320316652047

725. Patti G, Ricottini E, Nusca A et al. Short-term, high-dose Atorvastatin pretreatment to prevent contrast-induced nephropathy in patients with acute coronary syndromes undergoing percutaneous coronary intervention (from the ARMYDA-CIN [atorvastatin for reduction of myocardial damage during angioplasty--contrast-induced nephropathy] trial. Am J Cardiol 2011; 108(1): 1 - 7. doi: 10.1016/j.amjcard.2011.03.001

726. Han Y, Zhu G, Han L et al. Impact of Rosuvastatin on contrast-induced acute kidney injury in patients at high risk for nephropathy undergoing elective angiography. Am J Cardiol 2015; 115(7): 867 - 71. doi: 10.1016/j.amjcard.2015.01.007

727. Fu N, Liang M, Yang S. High Loading Dose of Atorvastatin for the Prevention of Serum Creatinine and Cystatin C-Based Contrast-Induced Nephropathy Following Percutaneous Coronary Intervention. Angiology 2018; 69(8): 692 - 699. doi: 10.1177/0003319717750903

728. Xinwei J, Xianghua F, Jing Z et al. Comparison of usefulness of simvastatin 20 mg versus 80 mg in preventing contrast-induced nephropathy in patients with acute coronary syndrome undergoing percutaneous coronary intervention. Am J Cardiol 2009; 104(4): 519 - 24. doi: 10.1016/j.amjcard.2009.04.014

729. Brar SS, Aharonian V, Mansukhani P et al. Haemodynamic-guided fluid administration for the prevention of contrast-induced acute kidney injury: the POSEIDON randomised controlled trial.

730. Lancet 2014; 383(9931): 1814 - 23. doi: 10.1016/S0140-6736(14)60689-9 Black C, Sharma P, Scotland G et al. Early referral strategies for management of people with markers of renal disease: a systematic review of the evidence of clinical effectiveness, cost-effectiveness and economic analysis. Health Technol Assess 2010; 14(21): 1 - 184. doi: 10.3310/hta14210

731. Chan MR, Dall AT, Fletcher KE et al. Outcomes in patients with chronic kidney disease referred late to nephrologists: a meta-analysis. Am J Med 2007; 120(12): 1063 - 70. doi: 10.1016/j.amjmed.2007.04.024

732. Smart NA, Titus TT. Outcomes of early versus late nephrology referral in chronic kidney disease: a systematic review. Am J Med 2011; 124(11): 1073 - 80. e2. doi: 10.1016/j.amjmed.2011.04.026